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ABSTRACT OF THE DISSERTATION
The Biological Burden of Antibiotic Resistance
In Staphylococcus aureus
by
Natasha Samantha Dean
Doctor of Philosophy, Graduate Program in
Microbiology and Molecular Genetics
Loma Linda University, March 2004
Dr. Anthony Zuccarelli, Chairperson

Antibiotic resistance is a major problem. Resistance is often mediated by genes
on bacterial plasmids and dissemination of resistance is commonly achieved by plasmid
transfer. The mechanisms of resistance that are presently understood suggest that
resistance is energetically costly. If this is generally true, resistance would reduce the
fitness of cells in the absence of antibiotics. We examined the hypothesis that resistance
reduces the fitness of microorganism and requires continuous selection to be maintained.
To test this hypothesis, we measured the effects of plasmid-borne resistance genes on cell
growth by comparing the growth rates of Staphylococcus aureus with and without 10
plasmids. Plasmid-ffee cells were mixed with equal numbers of plasmid-containing cells
and propagated serially through 10 cultures for 5 days without antibiotics. The ratio of
sensitive to resistant cells was measured at regular intervals by plating. The results show
that plasmids reduce the growth rates of a sensitive laboratory strain, 8325-4 and also the
native MRSA strain from which the plasmids were obtained.
Because of its growth reducing effect we selected plasmid pS A2 to test our
secondary hypothesis that the resistance function rather than the biological cost of
maintaining plasmids causes most of the growth rate reduction. Transposon mutagenesis

was used to create randomly distributed mutations saturating the plasmid. We analyzed a
major portion of the plasmid by enrichment experiments where 113 mutated plasmids
were mixed in equal proportions and grown serially for 28 days, through 56 transfers.
Using restriction analysis and DNA sequencing, we found that the final population was
highly enriched for mutations in a 3 kb region of the plasmid corresponding to the plactamase operon and two ORFs with homology to the abortive infection protein AbiK of
Lactococcus lactis. Pairwise competition experiments show that 8325-4 grows
considerably faster carrying pS A2 with blaZ mutations than it does with unmutated pSA2
and almost as rapidly as 8325-4 with no plasmid at all. We conclude that the biological
function of blaZ impedes the growth of cells. This is significant since p-lactamase,
unlike most resistance genes, is not known to affect the cellular apparatus for DNA,
RNA, or protein production.

xi

INTRODUCTION
The Problem of Antibiotic Resistance
In recent years, antibiotic resistant bacteria have become a great concern to the
medical community. There has been a marked increase in the number of species that
have acquired resistance to antibiotics, as well as an increase in the kinds of antibiotic
resistance. Enterococcus, Streptococcus, Staphylococcus, Salmonella, Pseudomonas
aeruginosa, Clostridium difficile and Mycobacterium tuberculosis comprise a
representative group in the growing number of microorganisms resistant to most
antibiotics.
Antibiotic resistance is not a topic to be taken lightly. Studies reveal that
nosocomial infections in critically ill patients increased intensive care unit stay by 8 days,
hospital stay by 14 days and death rate by 35%; post-operative wound infections
increased hospital stay on an average of 7.4 days (101). Enterococcus faecalis.
Mycobacterium tuberculosis and Pseudomonas aeruginosa are resistant to more than 100
drugs (72).
Antibiotic Resistance
Overview
Antibiotics work in a variety of ways. Some antimicrobial agents inhibit bacterial
cell wall synthesis. These agents include p-lactam compounds such as penicillins (e.g.
penicillin G, ampicillin and methicillin), cephalosporins and carbapenems, as well as
monobactams and p-lactamase inhibitors. (3-lactams inhibit the final stage of murein
synthesis. This, by some undetermined mechanism, triggers murein hydrolases to lyse
the cell. A related group of antibiotics that prevent a different step in cell wall synthesis
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are the glycopeptides, vancomycin and teicoplanin. Other agents have an antibacterial
effect by inhibiting protein synthesis. Representatives of this group include the
aminoglycosides, tetracyclines, macrolides and chloramphenicol which interfere with
ribosome function. In addition, there are antibiotics that inhibit DNA synthesis,
including quinolones, fluoroquinolones and sulfonamides. The rifampicins inhibit
bacterial RNA synthesis.
As varied as the categories of antimicrobial agents, so are the mechanisms of
resistance. One method of resistance includes alteration of the target. Resistance to
aminoglycosides, macrolides, penicillins, tetracyclines and vancomycin is mediated in
this fashion. Another method of resistance is to alter the permeability of the cell to the
antibiotic. A permeability barrier can be created by an impaired influx mechanism that
reduces the amount of antibiotic entering the cell or by an increased efflux mechanism
that actively pumps the antibiotic out of the cell. Such mechanisms confer resistance to
tetracyclines, macrolides and quinolones. Additionally, microorganisms may possess
enzymes that either alter or inactivate the antibiotic. For example, p-lactamases
inactivate penicillins by cleaving their p-lactam ring. Resistance to tetracycline and
chloramphenicol is also mediated by enzymatic inactivation of the antibiotic. In
descriptions of resistance traits that follow, we will emphasize examples observed in
Staphylococcus aureus.
A. Beta-Lactam Drugs: Penicillins
Basic structure. Chambers et al (28) describes the chemical composition of
penicillins. All penicillins have a “core” consisting of a thiazolidine ring that is attached
to a p-lactam ring. The P-lactam ring carries a secondary amino group (RNH-). The core
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structure, 6-aminopenicillanic acid, is essential to the activity of these antimicrobial
agents. The p-lactam ring is enzymatically cleaved by the bacterial enzyme P-lactamase.
Penicilloic acid, the product of this enzymatic cleavage, does not show antibacterial
activity.
Mode of action. P-lactam antibiotics produce a bactericidal effect by inhibiting
the membrane-bound enzymes responsible for catalyzing vital stages in the biosynthesis
of the cell wall. This is achieved by the antibiotic binding directly and covalently to one
or more of the penicillin-sensitive enzymes called penicillin-binding proteins (PBPs).
Specifically, bound penicillin prevents PBPs from catalyzing the transpeptidase reaction
of peptidoglycan synthesis. The transpeptidase reaction involves the removal of the
terminal alanine from the D-alanyl-D-alanine peptide chain of one murein subunit with
the creation of a bond to the penultimate alanine of another murein subunit. As P-lactam
drugs are structural analogues of the D-alanyl-D-alanine substrate, they become
covalently bound to the PBPs, thereby inhibiting them.
Mechanism of resistance. There are three main mechanism of resistance to the
penicillins: (i) cleavage of the P-lactam ring by p-lactamases/penicillinases, (ii)
alterations in the target PBPs that reduce their affinity to the penicillins and (iii) a
permeability barrier preventing penetration of the antibiotic into the cell (77). The first
two mechanisms are especially important to P-lactam resistance in S. aureus. The last
mechanism pertains particularly to gram-negative bacteria which have an intrinsic
permeability barrier mediated by their outer cell membrane.
(i) Inactivation of p-lactam drugs’. P-lactamase production appears to be the most
common mechanism of resistance, with the discovery and identification of more than 100
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distinct P-lactamases (28). In terms of p-lactamase mediated resistance, the action of
penicillin is prevented when the P-lactam ring of the antibiotic is hydrolyzed by Plactamase. These molecules are extracellular enzymes which are divided into four types,
A through D. In S. aureus, serotypes A and C have high activity. Genes for p-lactamase
production, blaZ or penP are usually plasmid encoded, but these resistance genes may
sometimes be found on the chromosome of the bacteria.
Studies have been performed on class A p-lactamases of gram-negative bacteria
to identify the amino acid residues involved in resistance to p-lactam drugs for these
organisms (95). TEM-1-p-lactamase, a class A enzyme, is encoded by the 6/<ztem-i gene
present on the Tn5 transposon. Amino acid alterations that confer resistance to most
broad-spectrum P-lactam antibiotics are located near the active site binding pocket of the
TEM enzyme. Many of the mutations located around the active site pocket result in
increased catalytic efficiency for hydrolysis of extended-spectrum P-lactam drugs.
Briefly, the catalytic mechanism involves a nucleophilic attack on the carbonyl group of
the P-lactam ring by Ser70 of a class A p-lactamase.
blaZ is the gene that codes for the p-lactamase enzyme. In S. aureus, blaZ is
carried by plasmids and is located on mobile genetic elements acquired from other
bacteria. Three S. aureus transposons carry the blaZ gene: Tn4001, Tn4002 and Tn552.
Tn552 encoded P-lactamase resistance is the most common in S. aureus plasmids.
The expression of P-lactamase is typically inducible. Many of the molecular steps
involved in the signaling pathway for penicillin induction of P-lactamase have been
elucidated (8, 51, 142). The players in the pathway are the gene products of blaRl, blaR2,
blal and blaZ. BlaRl regulates the expression of blaZ via Blal. Blal is the repressor of
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blaZ. When Blal is bound to blaZ, (3-lactamase expression is inhibited. When unbound,
blaZ is derepressed, transcription occurs and p-lactamase is produced.
BlaRl is a 66 kD, zinc metalloprotease and is autocatalytic. It is a sensortransducer with extracellular and cytoplasmic domains. The sensor domain of BlaRl is
extracelluar and binds penicillin drugs. When a P-lactam is bound to the sensor domain
of BlaRl, a signal leading to the derepression of blaZ is transmitted to the interior of the
cell via proteolytic cleavage of the cytoplasmic transducer domain. The specific cleavage
site in BlaRl has been determined to be R293 in the sequence KKSLIKR293RLINIKEA
(142). When the transducer is cleaved, it releases a 33 kD protein which is free to cleave
Blal.
Blal is a 14 kD protein that binds to DNA as a homodimer and is cleaved by the
cytoplasmic domain of BlaRl. The cleavage site in Blal is located between N101 and
FI 02 at the amino-terminal of the protein, within the sequence NH2KSLVLNi01F102AKNEELNN (142). It is cleaved into 11 kD and 3 kD fragments. The 11
kD fragment contains the DNA binding domain and the 3 kD fragment contains the
dimerization domain. It is still not certain whether BlaRl directly cleaves Blal or if other
proteins are involved. Evidence compiled by Cohen and Sweeney (29) suggests that the
product of a chromosomal gene, blaRl, may also play a role. In addition, it is still not
known whether BlaRl cleaves monomers or dimers of Blal or both.
The blaZ signaling pathway of S. aureus is unique in bacteria because it involves
a series of proteolytic cleavages to transmit a signal from the exterior to the interior of the
cell. A typical two-component system in bacteria depends instead on the phosphorylation
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or methylation of intracellular molecules to transmit a signal from a surface-bound
receptor.
Methicillin resistance is another important (3-lactam drug resistance mechanism in
S. aureus. Methicillin is a semi-synthetic penicillin derivative. Resistance to this 13lactam drug in S. aureus is of great concern to medical and scientific personnel.
Consequently, the medical challenges that result from methicillin resistant S. aureus
(MRSA) will be discussed in greater detail in a later section. In this section, we will
provide a basis for understanding the resistance mechanism of MRSA.
The genes for methicillin resistance are located on the chromosome. The players
in the signaling pathway for methicillin resistance are mecA mecRl, mecR2 and mecl.
mecA codes for a penicillin-binding protein, PBP2A (also called PBP2’) which has a
lower binding affinity for (3-lactam drugs than regular PBPs. PBPs are transpeptidases
involved in the construction of the bacterial cell wall.
The regulation of methicillin resistance resembles that of (3-lactamase expression.
The chromosomally located gene, mecRl, like the plasmid located blaRl, codes for a
sensor-transducer that is part of a two-component signaling system. Mecl is a repressor
of mecA. When Mecl is bound to DNA, PBP2a is not produced. When Mecl is unbound,
then mecA is transcribed and PBP2a is produced. Lewis and Dyke (74) found that Mecl
is also an effective regulator of blaZ and blal. MecR2, like BlaR2, is an accessory
molecule involved in regulating PBP2a production.
There are a number of auxiliary genes involved in the expression of high-level
methicillin resistance in S. aureus. The role of auxiliary genes was discovered through
the observation that different levels of resistance to methicillin occurred in strains of
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staphylococci that had similar levels of expression of the mecA gene and produced
comparable amounts of PBP2a protein (37). Researchers wanted to determine the
reason(s) for the differing phenotype in cells producing the same amount of protein. It
was postulated that one or more unknown cofactors were needed for high level resistance
to methicillin. Studies revealed that four genes, femA,femB, femC and femD, play an
important role in the expression of methicillin resistance.
(ii.) Alteration of the target: S. aureus has a chromosomally encoded resistance to plactam drugs via the mec region which confers resistance to methicillin, a |3-lactamase
resistant penicillin, by encoding altered PBPs. There are two proposed mechanisms of
PBP mediated resistance. The first is through mutations in the PBPs which provide
immunity to all (3-lactam antibiotics. The second mechanism is the result of the synthesis
of a new PBP having reduced affinity for p-lactam antibiotics. It is believed that these
altered or new PBPs are p-lactam-resistant transpeptidases which function in cell wall
thickening and in septum formation (77).
B. Aminoglycosides
Basic structure. Aminoglycosides have a hexose ring, either streptidine as in
streptomycin or 2-deoxystreptamine for all other aminoglycosides (27).
Mode of action. Aminoglycosides are taken into the bacterial cell in three stages
(77). During stage I, the antibiotic binds to outer surface components of the cell in an
energy-independent manner. For gram-negative bacteria, the antibiotic passes across the
outer membrane by passive diffusion via porin channels. In stage II, there is energydependent transport of the antibiotic across the inner cell membrane into the cytoplasm
and driven by the transmembrane electrochemical gradient (27). Aminoglycosides are
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positively charged and the cell has an internal negative charge. Stage III consists of a
second, more rapid uptake of the antibiotic into the cell which occurs after the first wave
of antibiotic molecules bind to the ribosomes (77).
Once inside the cell, the antibiotic binds to specific proteins of the 308 ribosomal
subunit and inhibits protein synthesis. Inhibition of protein synthesis occurs by three
different mechanisms (27). (i) They interfere with the initiation complex for peptide
formation, (ii) They induce misreading of mRNA which causes the incorporation of
incorrect amino acids into the peptide. This results in non-functional or toxic proteins.
(iii) They cause the dissociation of polysomes into nonfunctional monosomes. It is
believed that for the aminoglycoside streptomycin, the antibiotic binds directly to the 16S
rRNA and distorts the aminoacyl site (114). This prevents the correct positioning of the
tRNA for initiation of protein synthesis.
Mechanism of resistance. Three primary mechanisms of bacterial resistance to
aminoglycosides have been discovered. The first method of resistance to
aminoglycosides is via an alteration in the ribosomal target site. Mutations in the genes
encoding ribosomal receptor proteins can result in changes in the structure of the
ribosome such that it no longer binds the antibiotic or these receptor proteins may be
absent. A second mechanism of resistance is impaired uptake of the antibiotic that
diminishes the effective intracellular concentration of the antibiotic. This apparent
impermeability may be caused by factors that affect the energetics of the cell membrane
(77), however the precise mechanism is not known. It has been proposed that membrane
impermeability may be a result of genotypic changes such as mutations in or deletions of
porin proteins or other proteins involved in the transport and maintenance of the
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electrochemical gradient. Another suggested reason for impermeability is a phenotypic
change owing to growth conditions under which the oxygen-dependent transport process
is not functional (27). The third mechanism of resistance is the most common and is due
to the chemical inactivation of the aminoglycoside by specific enzymes.
Aminoglycosides may be acetylated at secondary amino groups by aminoglycoside
acetyltransferases (AAC), adenylated at hydroxyl groups by aminoglycoside
adenyltransferases (AAD) or phosphorylated at hydroxyl groups by phosphotransferases
(APH). Modified aminoglycoside antibiotics no longer bind to ribosomes and
accordingly are unable to inhibit proteins synthesis.
C. Tetracyclines
Basic structure. All tetracyclines have a common structure. Free tetracyclines
are crystalline, amphoteric substances of low solubility. They are available for use as
hydrochlorides which are more soluble (26).
Mode of action. Tetracyclines inhibit protein synthesis. Tetracyclines enter
bacterial cells by a dual mechanism involving passive diffusion and an energy-dependent
process (active transport). Once inside the cell, tetracyclines bind reversibly to the SOS
subunit of the bacterial ribosome. Binding to the ribosomal subunit sterically inhibits the
binding of the aminoacyl-tRNA to the acceptor site on the mRNA-ribosome complex.
Consequently, amino acids cannot be added to a growing peptide chain.
Mechanism of resistance. There are three main mechanisms of resistance to
tetracyclines. They include (i) decreased intracellular accumulation of the drug due to
impaired influx or increased efflux via an active transport protein pump, (ii) ribosome
protection due to the production of proteins which interfere with the tetracycline binding
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to the ribosome and (iii) enzymatic inactivation of tetracycline by chemical modification.
In S. aureus, resistance is due to active efflux of the antibiotic out of the cell.
Tetracycline resistance determinants may be chromosomally-encoded or plasmidencoded (77).
D. Macrolides, Lincosamides and Streptogramins
Basic structure. Macrolides are a group of closely related compounds
characterized by a macrocyclic lactone ring, usually containing 14 or 16 atoms, to which
deoxy sugars are attached (26). Erythromycin is the prototypic drug of this class of
antibiotics. Clindamycin is a lincosamide which is used extensively in clinical situations.
It is a chlorine-substituted derivative of lincomycin. Streptogramins are not used
clinically in the United States.
Mode of action. Macrolides, lincosamides and streptogramins inhibit protein
synthesis by binding to the SOS ribosomal RNA. This binding prevents the formation of
initiation complexes and aminoacyl translocation reactions.
Mechanism of resistance. Resistance to macrolides is usually plasmid-encoded
but may sometimes be encoded chromosomally. Three main mechanisms have been
identified. These include: (i) reduced permeability of the cell membrane or active efflux,
(ii) production of esterases that hydrolyze the antibiotic and (iii) modification of the
ribosomal binding site by either chromosomal mutation, or by methylation of the 32S
ribosomal RNA by a macrolide-inducible or constitutively produced methyl transferase
enzyme (26). In gram-positive organisms, methylation of ribosomal RNA is the major
mechanism of resistance. Lincosamides and streptogramins are structurally similar to the
macrolides and share the same ribosomal binding site, i.e. the SOS subunit. Therefore
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constitutive expression of the methylase enzyme also confers resistance to these
antibiotics. This resistance is usually referred to as MLS resistance.
Resistance to lincosamides may be due to one of three mechanisms. The first is
mutation of the ribosomal receptor site. The second is modification of the receptor by a
constitutively expressed methylase enzyme as in macrolide resistance which confers
cross resistance to macrolides and streptogramins. The third mechanism of resistance is
by enzymatic inactivation of the lincosamide. Finally, resistance to the MLS antibiotics is
an intrinsic property of the outer membrane of gram-negative bacteria which is
impermeable to these compounds.
Resistance to streptogramins in S. aureus can also be the result of enzymatic
inactivation. Streptogramin A and B are component molecules of the streptogramin
antibiotic. Streptogramin A can be inactivated by an O-acetyltransferase reaction and
streptogramin B can be inactivated by hydrolase activity (77).
In S. aureus, MLS resistance is caused by a single alteration in the SOS ribosome,
specifically the N6-dimethylation of an adenine residue in the 23S ribosomal RNA (77).
This alteration reduces the affinity of the ribosome for the antibiotic class. Evidence
suggests that the decreased binding of the drug is due to a conformational change in the
23 S rRNA rather than to methylation of the binding site for the antibiotic (77).
E. Quinolones/Fluoroquinolones
Basic structure. Quinolones are generally defined as 1-substituted 1,4-dihydro4-oxo-3-pyridinecarboxylic acids that have an additional ring fusion (140).
Fluoroquinolones are usually regarded as 6-fluoro (quinolone numbering) substituted
counterparts of the quinolones.
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Mode of action. The main target of fluoroquinolones in E. coli and other
bacterial species is DNA gyrase (topoisomerase II). DNA gyrase is a tetramer composed
of two types of subunits (A2B2). Specifically, it is the gyrase A protein that is the target of
fluoroquinolones. DNA gyrase has various functions in bacteria. It introduces and
maintains negative supercoils; it relieves torsional tension generated by DNA replication
and transcription; and it decatenates interlinked DNA.
Accordingly, quinolones block gyrase action and thereby inhibit DNA synthesis.
Quinolones are thought to trap the reaction at an intermediate stage after the gyrase has
broken the phosphodiester backbone of DNA. This cleaved DNA intermediate is called
the cleavable complex and consists of DNA covalently joined at its 5'-end to the A
subunit of the gyrase by a S'-phosphoryl tyrosine bond (43). The lesion consists of a
quinolone-gyrase-DNA complex containing a double-stranded DNA break. The selective
toxicity of this drug is based on the differential sensitivity of the bacterial and
mammalian gyrases. Human DNA topoisomerase II is orders of magnitude less sensitive
to fluoroquinolones than the bacterial gyrase. The bactericidal effect is thought to be the
result of attempted repair during the SOS response. More recently it has been found that
bacterial DNA topoisomerase IV is also a target of quinolones (144).
Mechanism of resistance. Resistance to fluoroquinolones is chromosomally
encoded. To date, no plasmid-encoded resistance determinants have been identified.
Topoisomerase-based resistance to fluoroquinolones occurs stepwise, with moderate
levels of resistance arising from single mutations in the target, either DNA gyrase or
DNA topoisomerase IV (144). For DNA gyrase, the mutation occurs in the A subunit
(116). A second type of resistance to quinolones is more common and is a result of
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changes in permeability. This permeability change confers low level resistance and is
seen most often in Klebsiella pneumoniae, Pseudomonas aeruginosa and Serratia
marcescens (116). Impermeability has also been identified in E. coli. Salmonella,
Enterobacter andProvidencia (111).
In S. aureus, resistance is due to (i) changes in the DNA gyrase A (gyrA) or B
{gyrB) subunits, (ii) changes in the A {grlA) subunit of DNA topoisomerase IV and (iii)
an efflux mechanism mediated by the membrane protein, NorA, which is chromosomally
encoded (57, 88).
Plasmids and Antibiotic Resistance
Resistance to antibiotics and antimicrobial agents may be encoded by genes on
the bacterial chromosome or genes located on extrachromosomal plasmids. Plasmids are
usually the means by which most antibiotic resistance determinants are first acquired.
Four plasmid classes, I - IV, have been defined for staphylococcal species (92),
though additional plasmid classes may exist. Plasmid classes are based on size, copy
number and resistance markers carried. For example, plasmids belonging to class I are
small, approximately 1-5 kb. They have a high copy number, usually 15-20 copies per
cell, and encode a single antibiotic resistance. Plasmids of class II are intermediate in
size and copy number. They encode a combination of p-lactamase and inorganic ion
resistances. Class III plasmids are large (40-60 kb) and encode multiple antibiotic
resistances, usually including gentamicin resistance. In addition, many plasmids in this
class are conjugative. Class IV consists of plasmids of intermediate size which encode a
combination of resistances: penicillin, heavy metals, aminoglycosides and fusidic acid.
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Some S. aureus strains, especially those isolated from clinical infections, contain
more than one type of plasmid and accordingly can be resistant to a wide range of drugs
(146). Accordingly, plasmids play a major role in the pathogenicity of this organism.
Factors Contributing to Increased Antibiotic Resistance
Misuse ofAntibiotics.
Of the factors contributing to the rise in antibiotic resistant bacteria, human
misuse and abuse plays a critical role. Such misuse includes indiscriminate prescribing
and dispensing of antibiotics and failure of patients to complete the full course of
antibiotic treatment. The microenvironment created by the constant use of antibiotics
generates a selective pressure that selects for organisms able to survive and propagate in
such an environment as the result of novel mutations, newly acquired genetic elements or
inherent resistance as a result of genetic diversity within a population.
Selection pressure refers to the many environmental conditions that act on
populations of microorganisms. Some individuals in the population may survive and
proliferate in a selective environment by virtue of novel alterations or mutations in their
genetic material. Most discourses on antibiotic resistance and the effect of selection
pressure examine selection in Darwinian terms. Accordingly, selection pressure allows
for the differential proliferation of a sub-population. The degree of success an organism
displays in its ability to proliferate in a selective environment is a measure of its fitness in
that environment.
Treating bacterial infections with less than optimal doses of antibiotics exerts a
selective pressure that is highly suited for selecting individuals in a population that are
incrementally more fit than the rest of the population. At sub-therapeutic levels, only the
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most sensitive organisms are killed. Those organisms in the population with an inherent
resistance to the antibiotic or with non-lethal mutations survive and propagate. The
selected organisms are more antibiotic resistant than the original population and can be
killed only with exposure to higher concentrations of antibiotics.
Use ofAntibiotics in Livestock.
The use of antibiotics in food animals is thought to contribute heavily to the
emerging resistance patterns in human pathogens. Although it is disputed by farmers and
veterinarians, there is mounting evidence to support this claim.
Antibiotics are used in animal husbandry to improve growth and maintain the
health of livestock. Antibiotic use falls neatly into three main categories: therapeutic,
prophylactic and nutritive (126). Many of the broad and narrow spectrum antibiotics
used for therapeutic treatment of infected animals are the same as those used in humans.
Unfortunately, many of the antibiotics used for nutritive purposes to promote growth
development are used at sub-therapeutic levels. This practice is believed to generate a
reservoir of drug resistant microorganisms in the environment. At low antibiotic levels,
the bacterial population is subjected to a selection pressure that effectively amplifies the
few microorganisms that are adapted to the environment.
There are well documented cases that link antibiotic use in animal husbandry to
antibiotic resistant bacterial infections in humans. In November 1999, a 62-year-old
Danish woman died from Salmonella-mducQd food poisoning (85). The pathogen was
Salmonella enterica serotype typhimurium DTI04. Scientific investigation revealed that
she contracted the infection from contaminated pork products that were traced back to a
single Danish herd. The herd had been treated with enrofloxacin, a quinolone compound
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similar to ciprofloxacin. Ciprofloxacin is used to treat human cases of salmonellosis.
This particular Salmonella strain was resistant to seven other antibiotics.
In April 2000, a 12-year-old boy from a Nebraskan farm acquired a multi-drug
resistant Salmonella infection from an infected cow (47). The cows had been given
ceftiofur, a cephalosporin, to treat severe diarrhea in the herd. The infecting strain of
Salmonella enterica serotype typhimurium was resistant to 13 antibiotics, including
ceftriaxone, a drug that is used to treat salmonellosis in children. The boy lived, but this
outcome had little to do with his course of antibiotic treatment. This report describes the
first case of a Salmonella “super-bug” observed in the United States. Shortly thereafter,
another case of ceftriaxone-resistant Salmonella infection was reported in a 4-year-old
Ohio girl. She contracted the infection during a visit to her grandparents’ farm.
A point of concern for investigators is the fact that ceftriaxone resistance is
encoded by a plasmid. The plasmid-borne nature of ceftriaxone resistance means that it
can be readily transmitted by horizontal transfer between bacteria. The efficacy of
ceftriaxone treatment in children should not be compromised as it is the main drug
prescribed by physicians for salmonellosis. Quinolone antibiotics like ciprofloxacin
cannot be used in children because they impede bone development.
Another link between antibiotic use in animals and antibiotic resistant bacteria in
humans is Campylobacter jejuni. Since 1994 when the FDA approved the use of
quinolone drugs in poultry, the incidence of quinolone resistant bacteria in humans
increased from 1% to 17% (112). Of greater concern is the emergence of vancomycinresistant strains of enterococcus (VRE). In Europe, enterococci resistant to vancomycin
seem to coincide with avoparcin use in livestock in this region. In 1994, Germany
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banned the use of avoparcin as a growth promoter for livestock. By 1997, they had
observed a decrease from 12% to 2.5% in the number of reported VRE.
Examples such as these are not surprising given the quantity of antibiotics
administered to animals each year all over the world. It is important to note that many
classes of antibiotics are shared between the agricultural community and the medical
community. Teuber (126) provides concrete numbers for examination: In France in
1989, 50 tons of P-lactam antibiotics were used to treat farm animals, along with 57 tons
of aminoglycosides, 99.6 tons of chloramphenicol, 116.8 tons of tetracylines, 37 tons of
macrolides, 138.6 tons of sulfonamides and 126.2 tons of other assorted antibiotics; in the
Netherlands for 1990, 300 tons of antibiotics was for veterinary use; and in the United
Sates for 1978, 558 tons of antibiotics and antimicrobials were added to animal feed for
growth promotion.
Prescriptions for Overcoming Antibiotic Resistance
Understanding how bacteria become resistant may suggest strategies for
minimizing its emergence and dissemination. From the mechanisms described above,
there would appear to be at least three main ways to overcome the problem of resistance.
The first is to continue developing new drugs that act by novel mechanisms and would be
immune to existing mechanisms of resistance. The second is to use existing antibiotics in
a manner that minimizes the emergence of resistant strains. A third strategy is to use our
knowledge of resistance mechanisms to favor the proliferation of antibiotic sensitive
representatives in bacterial populations. The work described here provides an
experimental foundation for the last strategy.
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The latter method for counteracting resistance is worthy of further investigation as
most resistances, by virtue of the mechanisms by which they are achieved, may impose
energetic burden on resistant cells. Resistance by efflux mechanisms, for example,
operates by means of new proteins that transport antibiotics out of the cell. These
function either by hydrolysis of ATP or by expelling the antibiotic at the expense of the
cells electrochemical gradient. By comparison, many resistance traits are the result of
subtle alterations in cellular components that are responsible for vital physiological
functions. It may not be apparent that they impose any energetic burden on cells.
However, if the altered component is an element of the genetic processing pathway or
another core activity of the cell, its function will be highly constrained by interactions
with other elements in the pathway. Alterations that make the component refractory to
antibiotic action are also likely to reduce the efficiency of its primary function.
Strategies to Control Antibiotic Resistance
From an evolutionary prospective, resistance is the effect of environmental
pressures acting on microbial diversity. It is unrealistic to think that the problem of
antibiotic resistance will ever be eliminated. However it is conceivable that the
emergence and dissemination of antibiotic resistance can be significantly reduced, the
persistence of resistant species minimized and the effectiveness of antibiotic therapy
improved.
Medical treatment is hampered by multiple-drug resistant bacteria. Patients
infected with these pathogens suffer firstly from the primary infection itself, and secondly
from the risks of protracted illness due to ineffective or inappropriate treatment. The
medical, psychological and economic consequences of antibiotic resistance are far-
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reaching. For this reason, researchers both in academia and industry have invested much
time and effort pursuing ways to reduce antibiotic resistance. Because drug resistance in
bacteria is not a simple problem, strategies to combat drug resistance must be novel,
ingenious, and varied.
The Centers for Disease Control, The National Foundation for Infectious Disease
and the World Health Organizations have all provided prescriptions for reducing the
appearance and spread of antibiotic resistance in both the hospital and the community.
Reduce the Spread ofAntibiotic Resistant Bacteria
This strategy, though simple, affects the spread of resistant microorganisms in
both the hospital and the community. It requires that individuals be aware of personal
hygiene issues like handwashing, especially in hospitals where healthcare workers have
been strongly implicated in the spread of bacterial infections between patients and that
hospital personal wear gloves and masks when in contact with infected patients.
Reduce Antibiotic Consumption
Studies show that antibiotic resistance correlates with use. Therefore, a key
strategy to reduce the number of resistant organisms is to lower the rate of antibiotic
consumption. Physicians are advised against over-prescribing antibiotics and against
prescribing antibiotics inappropriately such as in cases of viral infection. Physicians are
also admonished to prescribe antibiotics selectively. They are to use narrow-spectrum
antibiotics. Appropriate choices can be ascertained by culturing the pathogen,
determining its drug susceptibility and then choosing an appropriate antibiotic. Selective
prescription of drugs also includes effective dosing, in terms of drug concentration and in
the length of time the patient must take the drug.
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Antibiotic cycling
For decades, antibiotic cycling has been proposed as a useful means of
minimizing the emergence of resistant infections. Essentially, when one failing antibiotic
is replaced by another that requires a different mutation to confer resistance, the new
environment imposes a new selection that effectively controls the organism. There is
typically an extended period between the introduction of the antibiotic and the
appearance of significant numbers of bacteria resistant to the second drug. This “lag
time” is a window of antimicrobial success, where the antibiotic proves useful as a
therapeutic agent. Meanwhile, resistance to the first antibiotic tends to decline due to the
fact that it imposes a metabolic burden in the absence of the first antibiotic. This strategy
can be compromised by the problem of compensatory mutations that alleviate or
eliminate the selective disadvantage resistant bacteria face in a new, “drug-free”
environment.
Drug Discovery
Another strategy that scientists are actively pursuing is the discovery of novel
antimicrobial compounds. Within a specific drug class, new antibiotics are created by
modifying the physical and chemical properties of the drug, changing the specificity of
the target site or by developing novel combinations of antimicrobials. A successful drug
combination is Augmentin® (amoxicillin/clavulanate potassium) used in the treatment of
penicillin resistant bacterial species. Another successful drug combination more recently
released is Synercid® (quinupristin-dalfopristin, Aventis Pharmaceuticals). This drug is
the first streptogamin marketed in the United States and it is targeted for the treatment of
vancomycin-resistant Enterococcus faecium bacteremia and complicated skin infections
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caused by MSSA and Streptococcus pyogenes. Levaquin® (levofloxacin, a
fluoroquinone), Tequin® (qatifloxacin, a fluoroquinone), Azithromax® (azithromycin, a
macrolide) and Merrem® I. V. (meropenem, a carbapenem) are popular examples of
modifications of older drugs and are indicated for the treatment of nosocomial and multi
drug resistant pathogens.
In addition to adding new antibiotics to existing drug classes, a new drug class has
been developed. The oxazolidinones belong to a novel drug class of particular interest to
clinicians. Eperezolid and linezolid are two oxazolidinones that have great potential in
the treatment of gram-positive pathogens. Linezolid, which was FDA approved in April
2000 and is sold under the trade name Zyvox® (Pharmacia Upjohn), is marketed for the
treatment of nosocomial infections caused by MSSA, MRS A and penicillin-susceptible
Streptococcus pneumoniae. Oxazolidinones prevent bacterial protein synthesis in a
unique way. Specifically, they inhibit the formation of the 70S initiation complex by
binding to the SOS ribosomal subunit close to where it interfaces with the SOS subunit
(40).

Novel Dosing Regimens
This strategy is based on dosing regimens that take advantage of the mutant
selection window and requires bacteria to obtain two or more concurrent mutations in
order to survive and grow in the presence of antibiotic compounds (143). The
concentration of antibiotics needed to produce these resistance mutations is called the
mutant prevention concentration (MPC). Drug resistance develops within a particular
concentration range, termed the mutant selection window. This concentration range
differs for each antibiotic and for each bacterial species.
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In general, the borders delineating the mutant selection window are the minimal
inhibitory concentration, the point where growth inhibition of susceptible cells starts, and
the MPC, the point where growth of all targeted bacterial cells (including resistant ones)
are prevented. Effective drug therapy would involve the use of antibiotic concentrations
that approximate the MPC. The best way to achieve this concentration without a high
level of toxicity to the patient would be to use combination therapy with two or more
antimicrobial agents, where the pharmokinetics of each drug work synergistically to
reach the MPC. Because bacterial cells have less than a producing two or more
simultaneous mutations is greater than (143) this strategy has a high chance of reducing
the number of resistant cells in a bacterial population.
Vaccines
The concept of immunizing susceptible individuals in a community against
staphylococcal infections is a viable one. For starters, the use of vaccines to treat
microbial infections is not a new concept. Currently, effective vaccines exist for diseases
like rubella, measles, mumps, tetanus, pertussis, and diphtheria. Experimental vaccines
to target staphylococcal infections are currently being investigated. Phase 3 clinical trials
of a polysaccharide-protein conjugate vaccine (StaphVAX), consisting of S. aureus
serotype 5 and serotype 8 polysaccharides, has shown a 57% reduction in infection rates
of high-risk patients (136). It takes 10 to 14 days for antibody levels to become
protective against S. aureus and immunity lasts up to 40 weeks post-immunization. The
vaccine is undergoing a second Phase 3 trial since the effective period of immunity after
vaccination fell short of the proposed 54 weeks. In this second Phase 3 trial, the efficacy
of booster shoots will also be determined.
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Other promising candidates for vaccines exist but these have not yet reached
advanced clinical trials. Lee (65) reviews some of these vaccine candidates, including
antibodies targeting adhesins such as fibronectin-binding protein, collagen-binding
protein and fibrinogen-binding protein, and a nontoxic alpha toxin mutant. Other targets
include RNAIII which regulates toxin production in S. aureus (11), poly-1-6 P-D-TVsuccinylglucosamine which is a surface polysaccharide of S. aureus and S. epidermis (82)
and mecA gene of MRS A (93).
Antibiotic Resistance and Compensatory Mutations
Currently, there are two prevailing theories concerning the persistence of
antibiotic resistance. The first and commonly accepted view is that the abundance of
antibiotic resistant bacteria will decrease if antibiotic usage is reduced and control
measures are instituted (34, 71, 73, 76, 125, 137). This theory is based on the premise
that antibiotic resistant bacteria face a metabolic disadvantage in comparison to antibiotic
sensitive bacteria, in the absence of the selective pressure imposed by the antibiotic.
Stated simply, antibiotic sensitive bacteria should grow more rapidly than antibiotic
resistant strains in the absence of the antibiotic due to a reduced biological burden. A
search of the literature has proved sufficient evidence to support the biological burden
resistance genes place on the bacterial cells carrying them. The opposing view
concerning the persistence of antibiotic resistance in bacteria accepts that antibiotic
resistance does reduce the fitness of bacteria, but only initially. Resistant bacteria then
“adapt” to the metabolic disadvantage caused by resistance to antibiotics. This
adaptation comes in the form of compensatory mutations. Compensatory mutations refer
to subsequent genetic changes that improve the efficiency of the resistant component or
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changes in other components that compensate for the antibiotic resistant component. In
this view there is little possibility of reducing the abundance of resistant individuals
because their fitness is equivalent to that of the sensitive individuals in the population.
Compensatory mutations can occur which lower the fitness costs to the bacteria,
while allowing the microorganism to remain antibiotic resistant. The occurrence of
compensatory mutations has been detected in streptomycin- and rifampin-resistant E. coli
(99, 104, 105), streptomycin-resistant 5. typhimurium (13), isoniazid-resistant M
tuberculosis (107) and fusidic acid-resistant S. aureus (86). The research conducted by
these authors on compensatory mutations focused on resistance genes located on the
bacterial chromosome. Also, in these experiments, resistance was conferred by changes
(mutations) in genes that control the host cell machinery. For example, streptomycin
resistance was associated with decreased translation (104) and/or increased translation
errors (15) and rifampin resistance was associated with decreased transcription (99). It is
important to note that the second site mutation gives a fitness advantage to the resistant
cells as long as the original resistance is maintained. If this resistance is lost, the
compensatory mutation decreases the fitness of the cell to a level equivalent or less than
the cost of the original resistance mutation.
The interaction between the host bacterium and resistance plasmids has also been
studied. Most experiments examining this phenomenon have observed that resistance
plasmids also decrease the fitness of bacterial host cells (45, 52, 139, 139). An increase
in bacterial fitness was achieved by the loss of the resistance determinant from the
plasmid (30, 49, 68, 84, 89, 141) or by inactivation of the resistance gene (66). Other
researchers have noticed increased fitness without loss of resistance in plasmid based
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systems as has been observed for chromosomal systems. Bouma and Lenski (18),
McDermott et al (80) and Lenski et al (67) examined compensatory mutations that
occurred with pBR322, using E. coli as their model. In their studies, they observed
compensatory mutations which occurred after many generations such that the evolved
strain possessing an antibiotic resistance plasmid was more fit than the parental, plasmidfree strain. However, the compensatory mutations were located on the chromosome and
not the plasmid as was expected and from this the authors concluded that the host cells
plays a significant role in adaptation to the negative fitness costs (80).
Much of the work conducted on the effect(s) of resistance on bacterial fitness and
the role of compensatory mutations has focused on gram-negative bacteria like E. coli. It
is believed that what has been observed in E. coli and Salmonella is a universal
phenomenon and as such very little work has been done in gram-positive bacteria.
Consequently, the primary goal of the present study is to investigate the persistence of
antibiotic resistance and the effect of resistance on growth in gram-positive bacteria,
using S. aureus as the working model.
Bacterial Evolution
An Overview
Evolution in bacteria is a complex balance between the conservation of genetic
information through successive generations and the ability of the bacteria to adapt to
changes in their environment. These two processes occur simultaneously. Genetic
conservation is maintained by enzymatic mechanisms that ensure the faithful replication,
segregation and repair of DNA. Genetic diversity is generated by mutations,
recombination, gene silencing and the movement of transposable genetic elements,
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including plasmids, transposons and associated genetic material between bacterial species
and sometimes between bacterial genera (6, 145).
Genetic diversity is the raw material of the evolutionary process. In microbes,
selection pressures acting on genetic variation and reproductive and physical isolation of
microbial species are the two main categories of evolutionary forces (5). Although it has
long been thought that natural selection acted mainly on spontaneous point mutations,
recent studies show that many genomes have an inherent level of plasticity provided by
repetitive DNA sequences, overlapping gene motifs, transposable genetic elements and
horizontal gene transfer (106).
Evolution plays an important role in the process of infectious disease. Even in the
same species of microorganisms, some members are more virulent than others. In an
effort to understand diseases and the microbes that cause them, population and
evolutionary biologist study molecular epidemiology, the mechanism of pathogenesis,
and the area of intervention (69). Molecular epidemiology covers a broad area of
research, including phylogenetic relationships, routes of transmission, virulence genes,
drug resistance and vaccine-related antigens. Studies concerning the mechanism of
bacterial pathogenesis usually focus on the dynamics of population proliferation and
maintenance of bacteria. The environmental setting for population studies include the
laboratory and in the case of pathogenic bacteria, the infected host.
An understanding of population dynamics and evolution in relation to how
microorganisms penetrate, evade or succumb to a host’s immune defenses is relevant to
understanding the course of an infection. Because the host immune system can be viewed
as an ecological/environment niche and the cells of the immune system as factors
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influencing the process of natural selection, significant medical advances can be made
through the study of bacterial evolution and ecology. Intervention, the third area that
evolutionary microbiologists study draws data from the areas of molecular epidemiology
and pathogenesis to provide methods of preventing disease, containing outbreaks and
developing vaccines.
The emergence and dissemination of antibiotic resistance has provided a large
data pool for the study of evolution at the molecular level (molecular evolution).
Antibiotic resistance genes can appear as a result of classical molecular processes, e.g.
mutations, or they can appear through the action of mobile genetic elements like plasmids
and transposons.
Horizontal Gene Transfer and Diversity
Horizontal (lateral) gene transfer is the exchange of information between different
microbial strains, species or more distant taxonomic groups. The role of horizontal gene
transfer is an important subject in microbiology, especially as it relates to the emergence
of new pathogens and epidemics. Genetic information can be shared naturally between
bacterial species in several ways. These include transformation, transduction and
conjugation operating on mobile genetic elements. One main method of genetic exchange
is via mobile genetic elements. In bacteria, these mobile genetic elements are represented
in different forms, including plasmids, transposons and antibiotic resistance gene
cassettes. Depending on the type of mobile genetic element, this DNA can be found on
the bacterial chromosome or on a plasmid. For our discussion, we will concentrate on the
role plasmids play in transferring genetic information.
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Plasmids are self-replicating pieces of additional DNA that play an important role
in bacterial adaptation and evolution. They can move laterally between bacterial strains,
species and genera, thereby conferring immediate adaptability to the new host residing in
a hostile environment. They may also be biologically costly to bacteria that acquire them
while in a neutral or hospitable environment. Plasmids normally do not encode functions
essential to bacterial growth. Instead they tend to provide gene products that are
beneficial to the bacterium under specific environmental conditions. Examples include
genes for antibiotic resistance, conjugation, sugar utilization, colicin activity (E. coli) and
nitrogen fixation (117). When plasmids are obtained vertically, from ancestor to
descendants, then it is presumed that genetic adaptation occurs between the host
chromosome and the plasmid over time. For plasmids obtained horizontally, it is
presumed that natural selection would choose plasmids with high transmissibility that are
advantageous to the host and have a relatively low biologically cost.
Bacterial Fitness: The Evolution of Reproductive Success
Fitness Defined
In evolutionary terms, the fitness of an organism has been defined as reproductive
success. The ability of an organism to survive and reproduce is the most elemental
definition, but inherent in this definition is the assumption that the offspring themselves
are viable, they too being able to survive and reproduce. Also inherent in this definition
is the concept of adaptation. Those organisms that are best suited for their environment,
those that have adapted, are most likely to survive and reproduce. The concept of
competition is also interwoven in the definition of fitness. An organism that has adapted
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to its environment is more likely to be a successful competitor, greatly improving the
chances that it will survive and reproduce.
Fitness in bacteria can also be defined in much the same way. Kibota and Lynch
(58) defined fitness as cell viability and reproductive success. They measured the rate of
exponential growth. From a survey of the literature, many other researchers agree with
this definition; therefore bacterial fitness has largely been defined in terms of the growth
rate of the cell (59, 66-68, 110, 113, 128, 132).
Other authors, using this framework, have provided an explanation for fitness at
the metabolic level and how cellular metabolism influences growth. Dean (38) defined
fitness, biochemically, as being proportional to the flux through a metabolic pathway. An
optimal flux would approach a steady state and enzymes with small effects on flux will
have a smaller effect on fitness. Kurland (61) defined fitness as the maximum growth
rate of bacteria in an unchanging medium when all the metabolic compartments of the
bacteria are duplicated in the steady state in minimum time. Accordingly, the maximum
growth rate will require that each individual component of a metabolic pathway be
present at the optimal concentration and will also require that each biosynthetic
compartment of the bacterium operate at a maximum rate.
Additionally, Kurland (102) also defined fitness at the level of translational
accuracy and RNA processivity. Processivity, as used by the author, is a measure of the
degree to which full-length versions of a protein can be made during translation.
Alterations in this process usually result in the manufacture of incomplete or changed
proteins. Processivity errors ultimately affect the cell’s growth rate because cellular
energy is invested in making a product that may not be of use to the cell. Processivity
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errors are greater in antibiotic resistant bacteria because these errors provide the
mechanism by which resistances arise. Therefore processivty errors pose a greater
burden on antibiotic resistant cells than on antibiotic sensitive cells.
Using a mixed population of antibiotic sensitive and antibiotic resistant bacteria
as their population model, Andersson and Levin (4) propose that fitness is a complex
state, comprised mainly of three interrelated factors. These factors are: a) the relative
rates at which antibiotic resistant and antibiotic sensitive bacteria “compete” (how well
each bacterial category utilizes nutrients to reproduce and the rate at which they die) in an
infected host and in the environment; b) the means by which these bacteria are
transmitted between hosts and c) the relative difference on how antibiotic sensitive and
resistant strains are cleared by the host immune system. Regardless of the different ways
many authors have explained bacterial fitness, the common thread in their explanations is
cell growth as determined by an increase in the number of cells.
Staphylococcus aureus
An Introduction to the Pathogen
Ch aracteristics
Staphylococci are gram-positive, spherical bacteria approximately 1 pm in
diameter that typically grow in irregular, “grape-like” clusters. This characteristic
clustering is the result of staphylococcal cells dividing in a different division during each
round of division before the previously dividing cells separate. However, when grown in
liquid medium, they may grow singly or form short chains consisting of cell pairs,
tetrads, or longer configurations. The staphylococci are non-motile, non-sporeforming,
and non-encapulated. There are over 30 recognized species of staphylococci. Three
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species of staphylococci are of clinical importance: Staphylococcus aureus, S.
epidermidis and S. saprophyticus. Staphylococci are found regularly on clothing, bed
linens, and other fomites in human environments.
These microorganisms grow well on many different types of media in the
laboratory under aerobic or microaerophilic conditions. Cells grow best at 37°C but
pigment production is most efficient at room temperature, 20-25°C. S. aureus when
grown on solid culture media forms colonies that range in color from gray to deep golden
yellow. These colonies are morphologically described as round, smooth and raised.
Staphylococci are able to ferment carbohydrates and produce pigments that range from
white to a deep yellow. Fermentation of carbohydrates results in lactic acid production
without concurrent gas production. Some members of this class are part of the normal
microbiota of the skin and mucous membranes of humans. Other members of this class
are able to cause suppuration, abscess formation, pyogenic infections, benign food
poisoning as well as fatal septicemia. Other clinical characteristics of the staphylococci
include the ability to hemolyze blood, coagulate plasma and produce a large variety of
extracellular enzymes and toxins.
Staphylococci produce catalase, an enzyme that converts hydrogen peroxide into
water and oxygen. Catalase production has great clinical importance as this biochemical
characteristic serves to differentiate the staphylococci from the streptococci, another
group of pathogens of that are frequently involved in nosocomial and community
acquired infections.
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Infection and Disease
S. aureus is differentiated from the other staphylococci by the production of
coagulase. It is a major pathogen as well as an opportunistic pathogen. Although it
colonizes the skin and the anterior nares of healthy individuals, in most cases
colonization does not cause disease. This is good news as approximately one-third of all
adults are colonized with S. aureus at any given point in time and 25% are permanently
colonized. Nasal carriage in humans is thought to be between 40-50%. Almost every
person will become infected with S. aureus although the severity of the infection will
vary. The most common S. aureus infection is food poisoning, also called a toxinosis or
an intoxication, because symptoms result from the ingestion of preformed toxins.
Moreover, there are categories of individuals who are especially susceptible to
infection by S. aureus. These are neonates, the elderly and immunocompromised
individuals where the common denominator among them is a weak, poorly formed or
impaired immune system. The latter group is a heterogenous mix of individuals and
includes bum victims, patients in critical care wards, those receiving anticancer therapy
(chemo- or radiation therapy), those who have undergone minor surgery or received
prosthetic devices, individuals with underlying diseases that affect their immune systems
and anyone on immunosuppressive drugs. Secondary infections by S. aureus of immunesuppressed patients can complicate treatment, especially if the infecting strain(s) is drug
resistant.
Consequently, S. aureus is a major nosocomial pathogen. Approximately two
million hospitalizations a year result in nosocomial infections and S. aureus is one of the
most common causes. It is currently the leading cause of nosocomial pneumonia and
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surgical site infections, the second leading cause of nosocomial bacteremia (101) and the
leading cause of morbidity in such infections (7). The most common hospital-associated
infections caused by S. aureus are pneumonia, bacteremia, endocarditis, osteomyelitis,
septic arthritis, soft tissue abscesses, traumatic wound infections and post-operative
wound infections. Other diseases caused by S. aureus, although not as prevalent as they
once were, include scalded-skin syndrome, impetigo, subcutaneous and toxic shock
syndrome (TSS).
Because of colonization and persistent carriage of sometimes multiply resistant S.
aureus, community acquired staphylococcal infections are a major concern to clinicians
as well. The ramifications of this problem are apparent. A patient can be infected by his
own resident strains of S. aureus, as well as introduce the MRSA to hospitals where it
then spreads.
Pathogenesis and Virulence
S. aureus is one of the more resourceful pathogens. It is adept at entering the host
organism through wounds and other breaks in the skin and circumventing host defenses.
Different strains have varying degrees of virulence, but when viewed as a collective, S.
aureus is a formidable opponent with an arsenal of measures to avoid capture and
destruction by cells of the immune system.
Bacterial virulence is usually defined as the relative capacity of an infecting
organism to overcome available host defenses (118). It is a quantitative measure of an
organism’s ability to cause disease. In the laboratory, virulence is often quantified by
measuring the 50% infectious dose (ID5o) or the 50% lethal dose (LD5o). Virulence
differs from another frequently used term, pathogenicity, which refers to the ability of a
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microorganism to replicate within a specific animal and cause damage to host cells and is
qualitative (46).
An array of virulence genes contribute to the pathogenicity of S. aureus. The first
group of virulence genes we will discuss code for cell wall proteins collectively known as
MSCRAMMs or microbial surface components recognizing adhesive matrix molecules.
These molecules, which are a subgroup of the adhesin family of proteins, mediate
attachment of S. aureus to the extracellular matrix of host cells. MSCRAMMs include
Protein A (von Willebrand factor binding protein), fibrinogen-binding proteins also
called clumping factor or factor I, fibronectin-binding proteins and collagen-binding
proteins (138).
Pathogenic success may be contributed by one of two means: (i) being coated by
proteins from the host’s blood may help the bacteria to appear as self and thus remain
undetected by the immune system or (ii) adherence to cell matrix proteins allows the
infecting bacteria to attach to host tissue and quickly colonize a host organism. For
strains of S. aureus that can exist intracellularly, attachment would be the first step in
invasion of host cells. Attachment would also facilitate the degradation of the
extracellular matrix holding cells together (e.g. scalded skin syndrome) and would result
in an immune reaction that destroys tissue, allowing a release of nutrients for the bacteria.
Another advantage of tissue destruction is that the area of dead tissue would help to
protect the bacteria from phagocytic cells, antibodies and antibiotics because it is cut off
from the host’s blood supply (e.g. abscesses).
Coagulase, another virulence factor, helps to distinguish S. aureus from other
staphylococci and allows it to clot plasma and to escape phagocytosis. By possessing
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clotting activity itself, coagulase bypasses the normal human plasma clotting cascade.
Therefore, S. aureus may persist within the host through the aid of coagulase. It is
believed that coagulase deposits fibrin on the surface of these cells thereby preventing
their ingestion by polymorphonuclear leukocytes, or by preventing their destruction once
they’ve been ingested by phagocytes. Coagulase is also called clumping factor because it
binds to fibrinogen causing the bacteria to aggregate. In addition to these S. aureus
produces other virulence determinants. These include Protein A which is found only in S.
aureus, polysaccharide A, and capsular antigens.
S. aureus also possesses an arsenal of enzymes and toxins that contribute
significantly to its virulence. The function of these secreted proteins or exotoxins is to
allow the invading bacteria to convert host tissue into nutrients for sustained growth and
to limit the immune response. Nearly all strains produce and secrete nucleases, proteases,
lipases, hemolysins (a, p, y, 8), hyaluronidase and collagenase (41). Some strains also
secrete additional exotoxins that have potent effects on the host immune system and these
include the staphylococcal enterotoxins (SE) A-K, the exfoliative toxins (ET) A and B,
toxic shock syndrome toxin 1 (TSST-1), staphylokinase and leukocidin.
Enterotoxins types A, B, C1-3, D and E, are produced by approximately one-third
of all S. aureus species. SEA and SED are most frequently associated with food
poisoning (36) and to a lesser degree, SEB and SEC (41, 94). The exfoliative toxins ETA
and ETB are proteases responsible for staphylococcal scalded-skin syndrome, which
includes a variety of conditions such as localized bullous impetigo, Ritter’s disease,
Lyell’s syndrome and toxic epidermal necrolysis. The symptoms of the disease result
from the ETs separating the epidermis from the underlying tissue. The best studied ET is
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ET-A. This protease targets desmoglein-1 on the surface of keratinocytes in the
epidermis. This molecule is found only on the surface of epidermal cells and functions to
maintain keratinocyte cell to cell adhesion. TSST-1 causes toxic shock syndrome which
is defined by the presence of the following symptoms: fever, shock and a desquamative
skin rash. Other organs and body systems may be involved. This multisystem
involvement is the result of TSST-1 entering the bloodstream. Toxic shock syndrome can
be fatal if there is considerable shock and cell damage. The gene for TSST-1, tst, is found
in approximately 20% of all strains of S. aureus. This toxin is structurally similar to SEE
and SEC. TSST-1 and the staphylococcal enterotoxins are also pyrogenic toxin
superantigens (PTSAgs). All of the PTSAgs are encoded by genes found on variable
genetic elements. TSST-1 and SEE and SEC are present on pathogenicity islands (SaPIs)
(75).

Another exotoxin of clinical importance is staphylokinase. Staphylokinase
dissolves blood clots. Staphylokinase activity helps to destroy the extracellular matrix
and fibrin fibers (fibrinolysis) that hold cells together, allowing S. aureus to move
through tissue and may even help the bacteria to escape from abscesses. Exotoxins like
luekocidin and a-toxin, also called a-hemolysin, have the ability to destroy mammalian
cell membranes. Accordingly leukocidin derived its names from its ability to kill
leukocytes. Leukocidin consists of two protein components termed S and F. The S and F
components both have enzymatic activity, altering phospholipid metabolism and thereby
disrupting normal cellular activity. Alpha-hemolysin derived its name from its ability to
lyse hematocytes, the cellular components of blood.
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In addition to these virulence factors, S. aureus possesses genes that confer
resistance to a wide range of antibiotics substances: penicillins, aminoglycosides,
tetracyclines, quinolones, fluoroquinolones, lincosimides and macrolides. Resistance to
other antimicrobial agents is also a problem. These include resistance to mupirocin,
antiseptics, disinfectants and heavy metals such as cadmium and mercury.
Drug Resistant Strains
Methicillin-Resistant Strains: One subgroup that has proved most problematic is the
methicillin-resistant S. aureus (MRSA). These microorganisms are multi-drug resistant
and there has been an increase in the number of MRSA cases, worldwide. In the United
States alone, the percentage of S. aureus isolates that are MRSA increased from 2.4% in
1975 to 32% in 1992 (78). Methicillin resistance in S. aureus is usually associated with a
locus on the bacterial chromosome called the mec region. The mechanism of methicillin
resistance has been discussed earlier in this chapter. This group frequently displays
resistance to other antimicrobial agents.
Vancomycin-Tolerant Strains
Another area of resistance that is of major concern is the emergence of strains of
S. aureus with reduced susceptibility to the glycopeptide drug, vancomycin. The
effectiveness of vancomycin, a last-line defense antibiotic, has been compromised. In
1992, Noble et al (90) successfully transferred the wanA gene from enterococci to S.
aureus under laboratory conditions. The prospect of lateral gene transfer worried the
medical community and rightly so as this transfer of enterococcal vancomycin resistance
was soon observed in clinical isolates of S. aureus. Five years after the laboratory
transfer of resistance genes between closely related gram-positive bacteria, the first case
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of MRS A with reduced susceptibility to vancomycin was reported in Japan ((20, 20, 53).
Since then more cases have been documented in Japan (54), France (96), Thailand (130),
Greece (133) and the United States. In the U.S., cases were reported in Michigan (21),
New Jersey (22), and Illinois (23).
The first vancomycin-intermediate resistant S. aureus (VISA) fatality occurred in
March 1998 (100, 108). Intermediate vancomycin resistance has been defined as strains
with a minimal inhibitory concentration of 8 to 16 pg per milliliter. For the
microorganism to be considered to be resistant to vancomycin, the minimal inhibitory
concentration would have to be >32 pg/m. In July 2002, the first vancomycin resistant S.
aureus (VRSA) was identified in Michigan (24). A second VRSA isolate was identified
three months later in Pennsylvania (25). Both strains contained vanA from enterococci.
There is grave concern that the vanA gene is transferred via conjugation from
Enterococcus to Staphylococcus, which suggests that there will be more cases of VRSA.
The mechanism of staphylococcal resistance to vancomycin is being investigated. What
is known, however, is that vancomycin resistance in S. aureus differs from vancomycin
resistance in Enterococcus. Using a laboratory mutant, Sieradzki et al (109)
hypothesized that the staphylococcal mechanism involves alterations in the bacterial cell
wall and capture of antibiotic molecules at some distance away from the sites of cell-wall
synthesis.
Small Colony Variants
Small colony variants (SCV) of S. aureus play an important role in persistent
infection. They have been associated with persistent, recurrent antibiotic resistant
infections. SCV can arise among methicillin-resistant S. aureus.
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SCV are subpopulations that are phenotypically different from the parent strain.
These phenotypic differences include small size, absence of pigmentation, absence of Phemolysis and slow growth (98). A particular point that needs to be emphasized is the
small size. For a strain to be considered a SCV, it has to produce colonies that are at least
10-fold smaller than the parent. Other phenotypic differences include reduction in
coagulase production, decreased susceptibility to aminoglycosides and cell-wall active
antibiotics, and an auxotrophic requirement for mendadione, hemin, thiamine, or CO2
(97, 98) as well as an inability to ferment many carbohydrates, including mannitol and
xylose (83).
Studies have shown that the phenotypic changes evident in SC Vs are due to
disruptions in the electron transport chain. The small size of SC Vs is due to slowed
growth as a consequence of decreased respiratory metabolism and ATP production.
Defects have been found in hemin and menaquinone biosynthesis. This slow growth
affords SCVs a selective advantage and allows them to survive inside phagocytes and
endothelial cells. Another factor that allows SCVs to survive in cells of the host defense
system is that they produce reduced amounts of lytic toxins. This finding is significant
because the lower enzyme production means decreased bacterial cell death and ultimately
an increase in the number of viable cells that allow the bacteria to persist with host cells.
The SCVs can then re-emerge from these cells to cause chronic infections.
Let us explore in more detail the slow growing phenotype of SCVs. For
respiratory mutants of S. aureus, the slow growth previously mentioned may be due to
several factors. A direct effect of defects in the electron transport chain is the decreased
synthesis of teichoic acid. Teichoic acid is an important component of the gram positive
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cell wall. Teichoic acid biosynthesis is hampered because precursor molecules like
phosphatidyl glycerol are not generated in the absence of electron transport. Another
factor is the decreased production of ATP. We all know that ATP is the “currency” of
the cell and is used to do work, including cell wall biosynthesis. Therefore an indirect
result of electron transport disruption is decreased cell wall production and slowed cell
growth in comparison to the wild type. For example, S. aureus 6850, a clinical isolate,
had a generation time of 20 minutes whereas a menadione auxotrophic derivative of this
strain, S. aureus JB-1, had a generation time of 180 minutes (83). The inability of SCVs
to produce hemin blocks the production of cytochromes. Also, hemin auxotrophy may be
due to an inability of the organism to insert ferric iron in the pyrrole structure which is
part of the anabolic pathway for cytochrome synthesis. Adding hemin to the growth
environment reverses the SCV phenotype as S. aureus is permeable to hemin. A reversal
in the SCV phenotype can also be seen when menadione is added.
Electron transport is required for carotenoid biosynthesis as electrons are shuttled
from the ETS to the P450 system which allows for pigment production (83). Because
pigment production is linked to electron transport it is easy to understand how SCVs form
nonpigmented colonies. The need for shuttling of electrons also explains the inability of
SCVs to ferment many carbohydrates. When electron transport is interrupted, NADH
accumulates and this down-regulates the citric acid cycle. Fermentation of mannitol and
other carbohydrates are blocked because this process requires an intact citric acid cycle
for efficient utilization of such sugars.
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Biofilms
& aureus readily forms biofilms. The ability to form biofilms increases its
pathogenicity and makes it a formidable opponent to human health mainly because of the
resistance properties of biofilms. Decreased susceptibility to all antimicrobial agents is a
characteristic of bacterial biofilms and this property has raised the awareness of the
medical and scientific communities to factors that promote the development of biofilms.
The concept of biofilms was first introduced in 1978, and since then
microbiologists, engineers and computer scientists have helped to progress the study of
biofilms. Despite this, relatively little is known about their physiology and ecology and
how they contribute to their antibiotic resistance. Hopefully the increased interest in
biofilms and their role in infection will serve to as a platform to provide answers to some
of these questions.
A biofilm is a dynamic system that forms at phase interfaces, e.g solid-liquid and
air-liquid interfaces. A familiar example of a biofilm is dental plaque, but biofilms are
also associated with sewerage processing and food digestion. Biofilms are organized,
interacting, three-dimensional structures of microorganisms. They may include many
different bacterial species in an interactive multilayer environment with intervening
networks of water channels (31).
Biofilm formation can be divided into sequential steps. The initial step is
adhesion of individual bacterial cells to a surface and is considered to be a random event.
The adherent cells divide continuously and produce an exopolysaccharide matrix, also
called the glycocalyx or a linking film. The exopolysaccharide matrix joins and protects
the cells and provides a medium to which other cells attach creating a diversified
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community of bacterial species. Every new organism that binds to the exopolysaccharide
matrix presents a new surface, allowing for the defined grouping of microorganisms
characteristic of a polymicrobial biofilm (55). Biofilms exhibit an increased resistance to
antibiotics, antiseptics, host defenses and shear forces. For example, S. aureus colonizing
implanted medical devices exist as biofilms. SC Vs generated within the biofilms that
form on medical devices have diminished metabolic rates and this property to their
antibiotic insensitivity.
Research Significance
Drug resistance is medically and economically costly. Morbidity and mortality
rates for individuals infected with antibiotic resistant microorganisms are twice as high
for individuals infected with non-resistant microbes (1). This is due to the increased risk
of inappropriate drug therapy, the risk of transmission due to a longer course of the
disease and to the presence of an underlying condition that impairs the patient’s immune
defenses. The cost of antibiotic resistance is also related to the extra days of
hospitalization while treating resistant infections, additional costs for diagnostic testing
(e.g. susceptibility tests and resistance profiles), the use of more expensive drugs to treat
multi-drug resistant organisms, longer prescriptions, the cost of isolation facilities and the
establishment of programs to rid the ward or hospital of antibiotic resistant organisms (1).
In light of its increasing medical significance due to its multi-drug resistant
phenotype, efforts are being made to limit the emergence and dissemination of resistant
S. aureus. These include efforts to develop an effective vaccine (11, 65) and the search
for new classes of antimicrobials effective against gram-positive microorganisms (42).
The research described here provides information that may help to limit the rise of drug-
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resistant S. aureus, as well as increase our knowledge of resistance plasmids and their
biological burden to host bacterial cells. Understanding the dynamics of competition
between resistant and sensitive strains and identifying genetic factors that reduce the
growth of resistant strains in antibiotic-free environments may suggest strategies that
would move populations towards sensitivity.
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METHODS AND MATERIALS
Bacterial Strains
The effects of plasmid carriage on bacterial growth rate were tested in two
laboratory strains of Staphylococcus aureus (Table 1). The strains, S. aureus 8325-4 and
AZ450, are genetically related; both are derived from S. aureus NCTC 8325, which
harbors three transducing prophages integrated at specific locations on the chromosome.
The first strain, 8325-4, differs from NCTC 8325 in that it is cured of all three prophages
(91); the second strain, AZ450, is similar to RN4220, which is a restriction negative
derivative of 8325-4 (60, 115, 131); however AZ450 contains one phage. Neither strain
possesses any natural plasmids or any known chromosomal resistance markers. They are
therefore sensitive to antibiotics and heavy metals. Other bacterial strains used in this
project were S. aureus AZ1000, Escherichia coli XL 1-Blue MRF' and SURE® 2 (Table
1). Table 2 lists the plasmids used in this study. These plasmids were isolated from a
collection of methicillin-resistant S. aureus (MRSA) obtained from hospitals in southern
California (146). Most of the MRSA strains in this collection contain one or more
plasmids, each plasmid containing one or more resistance genes.
Generating Isogenic Strains
One of the prerequisites for studying the effects of resistance on bacterial growth
is the construction of strains that differ only in their antibiotic resistances. These isogenic
strains could then be used to test the hypothesis that plasmid carriage negatively affects
growth. We wanted to test the effects of plasmid carriage in both its source strain (a
clinical isolate) and in a laboratory strain. The host background (i.e., the chromosomal
gene complement) was to be the same for the isogenic pair, regardless of host cell origin.
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Table 1. List of bacterial strains. The strains listed here were used in growth rate
experiments, relative growth rate experiments and transformation experiments.
Bacterial
Species
Staphylococcus
aureus

Strain
8325-4

Genotype or
Phenotype

Reference

phage free derivative
of NCTC 8325
(strain has been
cured of three
prophages: Pll,
P12, and P13)

Novick, R. (1967) Virology
33:155-166

Kreiswirth, B. et al (1980)
Nature 305:709-712

Supplied by John J. landolo,
Kansas State University,
Manhattan, KS

Staphylococcus
aureus

RN4220

8325-4 r-

Staphylococcus
aureus

AZ450

A strain similar to
RN4220 containing
an unknown
prophage

Staphylococcus
aureus

AZ1000

8325-4 (Rif, Fusr)

Escherichia coli

XL 1-Blue
MRF

Stratagene, La Jolla, CA
#200230

Escherichia coli

SURE 2

Stratagene, La Jolla, CA
#200152

Mec- methicillin
Cd- cadmium
Rif- rifampicin
Fus- fusidic acid
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spontaneous mutants of
8325-4 created in our lab by
G. P. Harding

Table 2. List of plasmids used in this research project. AZ is a designation for clinical
isolates obtained from hospitals in southern California. Isolates were obtained from
active infections and samples preserved for long-term study.

Source
Strain

Size
(kb)

Resistance Marker(s)

Derivative
Designation

pSAl

AZ131

28.0

(3-lac, Cd, Ery, Kan, Tob,
Hg, As

8325-4[pSAl]
AZ450[pSAl]

pSA2

AZ28

25.9

(3-lac, Cd, EtBr

8325-4[pSA2]
AZ450[pSA2]

pSA3

AZ12

21.9

P-lac, Cd

8325-4[pSA3]
AZ450[pSA3]

pI9789

NCTC
8325

19.7

Cd, Hg, cpHg, Ars

8325-4[pI9789]
AZ450[pI9789]

pSKo10

NCTC
8325

19.4

Cd, Hg, cpHg, Ars

8325-4[pSKo10]
AZ450[pI9789]

pI9789::Tn552

NCTC
8325

26.4

Cd, Hg, cpHg, Ars, p-lac

8325-4[pI9789::Tn552]

pl4Cd

AZ159

30.3

P-lac, Cd, Ars

8325-4[pl4Cd]
AZ450[pl4Cd]

pl4Kan

AZ159

22.2

Gen, Kan, Tob

8325-4[pl4Kan]
AZ450[pl4Kan]

pl5Ery

AZ144

11.9

Ery

AZ450[pl5Ery]

pl6Cd

AZ148

32.7

Cd, Ars

AZ450[pl6Cd]

pl8Cd

AZ139

28.4

Cd

AZ450[pl8Cd]

pl8Neo

AZ139

43.3

Neo, Cd, Gen, Tob, Kan

AZ450[pl8Neo]

p39Cd

AZ64

27.3

P-lac, Cd, Hg

8325-4[p39Cd]

P39Kan

AZ64

23.7

Kan, Gen, Tob

8325-4[p39Kan]

p41Cd

AZ 217

27.7

Cd, P-lac

AZ450[p41Cd]

Plasmid
Name

Ars- arsenate
(3-lac- p-lactamase production
Cd- cadmium
Ery- erythromycin
Gen- gentamicin
Hg- mercury
(pHg- phenylmercuric acetate

Kan- kanamycin
Neo- neomycin
Tet- tetracycline
Tob- tobramycin
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The first method we used to obtain plasmid-free cells utilized compounds or
conditions that preferentially interfere with plasmid replication compared with replication
of the bacterial chromosome. Sustained exposure to such agents should generate a
subpopulation of bacteria that were cured, i.e., had lost the resistant plasmid(s). Cured
cells were identified by their inability to grow on medium supplemented with the
antibiotic for which that plasmid provided resistance.
Five clinical isolates of S. aureus were selected for curing: AZ139, AZ149,
AZ153, AZ159 and AZ2\1 (Table 3). Curing was attempted using growth at elevated
temperatures, or elevated temperatures combined with growth in the presence of chemical
agents such as ethidium bromide (16), novobiocin (81), enoxacin (48) or L-ascorbic acid
(2), which are known to interfere with DNA replication. The working premise for a
curing experiment is that plasmid replication is preferentially inhibited such that in
successive divisions there will be daughter cells that do not receive a copy of the plasmid
and so are plasmid-free versions of the parent cell.
In the first curing experiments using elevated temperatures, cultures of the
selected strains were incubated overnight in a shaking water bath at the highest
temperature that would allow growth (39°C to 43°C). Samples of the treated cultures
were streaked onto trypticase soy agar (TSA [Difco brand]; BD Diagnostic Systems)
plates and incubated overnight at 37°C. From these plates, several hundred colonies were
individually inoculated into 0.2 ml brain heart infusion (BHI) broth (Difco) in the wells
of microtiter plates. After overnight incubation at 37°C, a sample of each well was
mechanically transferred to a 150 mm TSA plate containing the antibiotic to be tested. In
each case, the resistance determinant for that antibiotic was known to be located on a
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Table 3. List of strains used in the curing experiments and the plasmids they possess/ AZ2X1 was cured by heat alone. For
AZ139, AZ149, AZ153 and AZ159 curing efforts combined high temperatures with either ethidium bromide, novobiocin,
enoxacin or L-ascorbic acid.
Strain

Curing Conditions

Plasmid
Profile
Resistance
Markers

oo

Temperature

Ethidium
Bromide

Novobiocin

Enoxacin

Ascorbic
Acid

41.5°C

2.8 x 10 -5
mg/L

0.875 mg/L

2 mg/L,
4 mg/L,
6 mg/L

2 mM,
4 mM,
6 mM

Ery
Cd
Tet

42°C

4.5 x 10'5
mg/L

0.250 mg/L

2 mg/L,
4 mg/L

7 mM,
8 mM,
9 mM

pl5Ery
pl8Cd
pT181

Ery
Cd
Tet

39.5°C

4.5 x 10'5
mg/L

1.25 mg/L

2 mg/L,
3 mg/L

2 mM,
4 mM,
6 mM

AZ159

pl4Kan

Gen, Kan, Neo, Tob

42°C

2.5 x 10-5
mg/L

1.85 mg/L

1 mg/L

3 mM
6 mM

AZ2171

p41Cd

Cd, P-lac

42°C

No
experiments
conducted

No
experiments
conducted

No
experiments
conducted

No
experiments
conducted

AZ139

plSNeo
plSEry
pT181

Neo, Cd, Gen, Tob,
Kan
Ery
Tet

AZ149

pl5Ery
pl8Cd
pT181

AZ153

P-lac- P-lactamase production
Cd- cadmium
Ery- erythromycin
Gen- gentamicin
Kan- kanamycin

Neo- neomycin
Tet- tetracycline
Tob- tobramycin

plasmid. The concentration of antimicrobial agents used to detect daughter cells lacking
a plasmid are as follows: kanamycin (10 pg/mL), gentamicin (5 pg/mL), ampicillin (3
pg/mL), neomycin (10 pg/mL) erythromycin (5 pg/mL) and cadmium (35 pg/mL).
Growth at elevated temperatures was successful in curing only AZ217. We added
chemical inhibitors of DNA replication to improve the curing rate for the remaining four
strains: AZ139, AZ149, AZ153 and AZ159. We used the minimum inhibitory
concentration of the chemicals listed in Table 3 for each of the remaining strains. Each
strain was inoculated individually into trypticase soy broth (TSB; Difco) with the
corresponding concentration of the antimicrobial agent. After this step, the procedure
was similar to the method previously described.
After we cured several clinical isolates by these methods, we then attempted to
find spontaneously cured cells in cultures after serial propagation. Plasmid-containing
cells were grown at 37°C without antibiotics and serially propagated every 24 hours for
10 days. At the end of this period, samples of the cultures were spread onto TSA plates
and replicated plated onto BHI with antibiotics. Again, cured isolates were identified by
the fact that they did not grow on medium with antibiotic, whereas growth of the parent
cell was not inhibited by the antibiotic at the same concentration.
The third method we used to construct strains that differed only in the presence or
absence of an antibiotic resistant plasmid was to simply introduce resistance plasmids
into sensitive bacterial strains by electroporation. We used S. aureus 8325-4 and AZ450,
two well-characterized plasmid-free laboratory strains. S. aureus AZ450 cells were
prepared for electroporation according to Schenk and Laddaga (103). An overnight
culture of AZ450 was established by growing cells at 37°C in 10 ml of B2 broth [10 g
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casein hydrolysate, 2.5 g yeast extract, 1 g K2HPO4, 5 g glucose, 25 g NaCl (pH 7.5) per
liter]. The overnight culture was then added to 250 ml of B2 broth and grown for one
hour with shaking at 37°C to an OD578 of 0.5 - 0.65. The culture was centrifuged for 10
minutes at 8,000 x g. The cells were washed four times by resuspending the pellet three
times in an equal volume of sterile de-ionized water and once in 50 ml of 10% glycerol,
centrifuging for 10 minutes at 8,000 x g after each resuspension. After the final wash, the
cells were resuspended in 8 ml of 10% glycerol and dispensed in 500 pi aliquots into 1.5
ml microcentrifuge tubes. These electroporation-ready cells were stored at 80°C for
future use.
Prepared cells of AZ450 were transformed with plasmid DNA by electroporation
using the method of Augustin and Gdtz (9). We added 1 pi (1 - 2 pg) of purified plasmid
DNA to 50 pi of electroporation-ready AZ450 cells and incubated the cell/DNA mixture
for 30 minutes at 25°C. At the end of the incubation, we again mixed the cells and
transferred them to a 0.2 cm cuvette. The cells were electroporated using the Gene Pulser
(Bio Rad; Hercules, CA) with control settings at 100 G, 25 pF and 2 kV. To facilitate
recovery from the electric shock, we added 950 pi of SMMP50 [5.5 parts SMM buffer (1
M sucrose, 0.04 M maleic acid and 0.04 M MgCh, pH 6.5); 4 parts 7% Penassay broth
(Gibco); and 0.5 parts filter sterilized 10% bovine serum albumin (BSA)] and incubated
them for 3 hours at 37°C with shaking. Transformants were detected by growth on
medium supplemented with an antibiotic whose resistance trait was known to be encoded
by the plasmid. Plasmid DNA was extracted and examined by gel electrophoresis to
verify that each isolate contained a single plasmid species. Each cell line was given a
unique designation (Table 2). This transformation procedure was repeated using 8325-4.
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Growth Rate Experiments
At the start of our investigation, we thought that the growth rates of cells might be
sufficiently reduced by plasmid carriage such that the differences in growth rates would
be detectible by plotting optical densities of the growing cultures.
The growth rate of S. aureus AZ450 was compared to isogenic bacterial strains
transformed with single plasmids. Parallel cultures of S. aureus AZ450 and a plasmidcontaining derivative were grown with shaking at 37°C in Nutrient broth (Difco
Laboratories). The optical densities of the cultures at 520 nm were measured at regular
intervals for 12 hours: every 2 minutes for 8 hours and then every 30 minutes for an
additional 4 hours. The logarithm of absorbance was plotted as a function of time. The
slope of the linear section of the graph was determined by performing a regression
analysis using Sigma Plot. The resulting line was defined by at least twelve data points
and represented 3 hours of growth in log phase. The doubling time observed for each
strain was calculated from the slope using the following formula:
d= log (2) = 0.301
slope
slope

Relative Growth Experiments
Rationale for Procedure
Before describing how the relative growth experiments were performed, it is
useful to explain the theoretical premise behind their design. An important point to
consider is that the isogenic strains we generated (plasmid-free and plasmid-containing S.
aureus derivatives) did not show discemibly different growth rates using simple optical
density measurements (see “Growth Rate Experiments”). Consequently, we needed a
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method that would be sensitive to much smaller differences in growth rate. The criteria
which proved critical to our design are listed below:
1. Standardized Growth Conditions: We wanted to minimize the possibility that
differences in growth could be considered experimental artifact as a result of differences
in growth conditions. In our estimation, the best way to standardize growth conditions
was to grow the paired strains of antibiotic sensitive and antibiotic resistant S. aureus
together in the same environment. Additionally, the cultures were grown for an extended
period of time in serial cultures to allow small differences in the growth rate (as low as
0.01%) between the two strains to produce easily measurable differences in the relative
numbers of the two cell types (>10%). Ultimately, we hoped to detect small differences
in growth rates by the changing ratio of sensitive to resistant cells at successive sampling
times.
Our original intent was to perform the relative growth experiments in a
continuous growth chamber or chemostat. In such devices a logarithmic growth rate is
maintained by continuously removing liquid (and cells) from the growth chamber while
simultaneously replacing the volume with fresh medium. An absolute requirement fro
the successful operation of a chemostat is that the culture volume be efficiently mixed
and that the withdrawn fraction be a representative sample of the total. We were unable
to satisfy these requirements. Within 24 hours of starting the chemostat S. aureus cells
established biofilms on the vessel walls and other internal components. This occurred
whether the internal surfaces were glass, siliconized glass or Teflon. Consequently, we
were forced to resort to serial batch cultures.
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In order to determine the time period for the relative growth experiments, we first
calculated (i) the minimum number of doubling events (generations) needed to create a
10% difference in the numbers of the two cell types when one of the strains grew 0.01%
more slowly than the other and (ii) the time required to obtain that number of generations
using the serial batch culturing procedure of the standard growth rate experiments. It was
determined that a growth period of five days (or 10 serial passages) was required to
produce a 10% difference in the numbers of sensitive and resistant cells in the mixed
population. Our experimental design also took into consideration the phases of a
standard bacterial growth curve. To minimize the time that cells were in stationary phase
and thereby reduce the likelihood of genetic changes that tend to occur during this phase,
we designed the process so that transfers were performed just as the cultures left
logarithmic growth. To accomplish this, we transferred only a small volume of the parent
culture into the new culture flasks which contained a fairly large volume of fresh
medium. Both our calculations from the growth rate experiments and our direct
measurements indicated that the cells were in log phase for most of the 12-hour
incubation period.
2. Sampling considerations and statistical analysis'. Regular samples of the growing cells
were needed to monitor the change in the growth rate of the two strains. We chose to
sample each subculture before transfer. Four of the eleven samples from the relative
growth experiments were plated. The ratio of sensitive to resistant cells from these
samples was used to graphically represent the change in the ratio of cell types.
In order to get statistically meaningful data, each sample was used to prepare
thirty plates. Each plate counted as an independent, replicate sample. Next, we needed
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to discriminate between sensitive and resistant cells without systematically excluding
either cell type. Finally, measurements of the number of sensitive cells must be paired
with the number of resistant cells in the same sample to improve the statistical
comparison. We achieved this by plating the sample of mixed cells onto medium without
any antibiotic selection. Once the colonies were grown and counted, this value
represented out total number of cells in that sample. The sample was then replica plated
onto medium with antibiotics which allowed only the resistant cells to grow. We then
subtracted this number from the total number of cells growing without selection to obtain
the number of sensitive cells in the original population. We were able to graphically
represent the change in ratio over time by plotting the mean ratio for each of the four
plating events. To obtain the mean ratio, we consistently divided the number of sensitive
cells by the number of resistant cells for each of the thirty paired plates and then averaged
these thirty ratios. Design of the plating experiments were performed with the assistance
of Dr. Jay Kim, a statistician from the Loma Linda University School of Dentistry.
Procedure
Pairs of strains were co-cultured to compare the relative growth rates of plasmidffee and plasmid-containing strains of S. aureus. Figure 1 outlines the steps of the
relative growth experiments. Sensitive and resistant strains of S. aureus were grown
separately in TSB without antibiotics at 37°C for 15-16 hours with constant agitation. At
the end of the growth cycle, we recorded the optical density at 520 nm for each of the
cultures using a Beckman DU650 spectrophotometer. Cultures were used to initiate the
relative growth experiment when they had similar OD520 values.
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To start the relative growth experiments, we mixed 500 pi of the sensitive and
resistant cultures in a 1.5 ml micro-centrifuge tube by vortexing for 30 seconds. We then
added 100 pi of this bacterial mixture to 500 ml of Nutrient broth in a 2 L flask and
mixed well by hand. The medium did not contain any antibiotics and represented the first
experimental flask in a series of 10 subcultures. The mixed culture was incubated with
shaking at 37°C for 12 hours and at the end of 12 hours, 100 pi of culture was transferred
to a second flask of fresh Nutrient broth. Serial cultures were propagated in this manner
every 12 hours for 5 days.
We monitored the loss of plasmids from the resistant strain by propagating the
plasmid-containing strain alone through an identical series of flasks, under the same
conditions described for the mixed population of cells. One milliliter samples of the
cultures were taken at the start of the relative growth experiment and at the end of each
growth cycle. The samples were centrifuged for 5 minutes at 14,000 rpms in an
Eppendorf 5417C centrifuge to harvest the cells. The supernatant was aspirated and the
pellet was resuspended in 1 ml of 10% glycerol. All samples were labeled and stored at 80°C. In total, eleven samples were preserved from each series of flasks.
We determined the difference in the relative growth rates of the two strains in the
mixed population of cells by plating on selective media. Briefly, we serially diluted the
samples and spread 100 pi of the appropriate dilution onto thirty antibiotic free TS A
plates and incubated the plates overnight at 37°C. The number of colonies growing on
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Figure 1. Procedure and conditions for the relative growth experiments. Serial batch cultures were propagated every 12 hours
for 5 days. Samples were collected at regular intervals and used to inoculate TSA plates. Colonies growing after 18 hour
incubation at 37°C were then replica plated onto antibiotic containing medium. The difference between the number of colonies
growing on TSA and antibiotic media were used to generate the ratio of sensitive to resistant cells. Changes in this ratio were
displayed graphically.

the TSA plates were counted and recorded. The colonies on these plates were replica
plated onto TSA plates containing the appropriate antibiotic. After overnight incubation
at 37°C, the colonies on the antibiotic-containing replica plates were counted and
compared with the number of colonies on the corresponding master plates without
antibiotics. We used these numbers to determine the ratio of sensitive to resistant cells in
the mixture used to initiate the series and to determine the change in this ratio throughout
the experiment. The sampling procedure was similar for the control flasks; however, we
prepared only 10 plates instead of thirty. After overnight growth these were replica
plated to fresh plates containing antibiotic. Comparisons between the original and replica
plates detected the appearance of cells that had spontaneously lost the plasmid and
become antibiotic sensitive. The data are presented in graphical form showing the ratio
of sensitive to resistant cells in the initial inoculum and at the end of growth of the third
flask, the seventh flask and the tenth flask.
Statistical Analysis
In order to generate the graphs representing changes in the ratio of sensitive to
resistant cells during the course of the 5 day relative growth rate experiments, we first
needed to determine the ratio of sensitive to resistant cells for each of the samples. For
experiments performed in AZ450, the sample plates were unpaired. In this case, TSA
plates with and without antibiotic were inoculated separately. The TSA plates without
antibiotics gave us a value for the total number of colonies per plate and the antibiotic
plates gave us a value for the number of resistant colonies. The difference between these
two values was the number of sensitive, plasmid-free colonies. To determine the ratio of
sensitive to resistant colonies for this strain, the mean number of sensitive colonies on 30
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plates was divided by the mean number of resistant colonies on 30 plates. This provided
us with the ratio of the means. Though this value was useful, we found that greater
statistical power could be obtained if the colony counts were paired. Consequently, in
subsequent experiments, 30 plates without antibiotic were spread first. After incubation,
the colonies were replica plated to antibiotic containing medium. By this means we
determined the number of sensitive and resistant colonies per plate, individually for all 30
plates. We calculated the ratio of sensitive to resistant cells for each of the 30 pair of
replica plates. Then we determined the mean standard error and as 95% confidence
interval for these thirty ratios. The same plating and calculations were performed for the
starting inoculum and the starting inoculum and the samples obtained at the end of
transfer 3, transfer 7 and transfer 10. The data was analyzed using the statistical package
included in Microsoft® Excel. In addition to the mean, we were able to determine the
standard error and 95% confidence interval (C.I.) for each sample.
Conjugation Experiments
For three of the plasmids, pSAl, p39Kan and pSKo10, we observed a steady
decline in the number of sensitive cells and in the mixed population. By the end of the
relative growth experiments, there were few detectable sensitive cells. We suspected that
plasmid transfer had converted sensitive cells to resistance by conjugation. To examine
the possibility that conjugation was occurring in these experiments, we tried to detect
conjugation of plasmid pSAl using the polyethylene glycol (PEG)-mediated transfer
method (129). We used AZ450 as the donor cell and S. aureus AZ1000 (Table 1) as the
recipient strain. Plasmid pSAl possesses resistance to (3-lactam drugs and AZ1000 has
chromosomal resistance to rifampicin and fusidic acid; it does not contain any plasmids.
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We selected conjugants by growing the mixed culture on medium containing ampicillin,
rifampicin and fusidic acid. Only AZ1000 cells that had acquired copies of pSAl would
be able to grow on the triple antibiotic plates.
Briefly, AZ450 containing plasmid pSAl (designated AZ450[pSAl]) and
AZ1000 were grown separately in 5 ml TSB at 37°C for 18 hours. The cells were then
pelleted for 10 minutes at 7,000 x g in a Sorvall (Newtown, CT) centrifuge. The
supernatant was discarded and each pellet was resuspended in 5 ml BHI broth containing
40% PEG (w/v). The resuspended cells were then mixed in the ratio of 1 ml of
AZ450[pSAl] to 3 ml AZ1000. This mixture was incubated at 37°C for 5 hours with
gentle shaking at 175 rpm. After five hours, the cells were again centrifuged for 10
minutes at 7,000 x g. The pellet was resuspended in 500 pi BHI and 100 pi was spread
on BHI agar plates containing rifampicin (25 pg/ml), fusidic acid (5 pg/ml) and
ampicillin (3 pg/ml). This procedure was repeated with 8325-4[pSAl] as the potential
donor and AZ1000 as the recipient. The data obtained from these experiments suggested
that AZ450 facilitated plasmid transfer. Thereafter, 8325-4 was used for all relative
growth experiments even though it was more difficult to introduce the desired plasmid
into this strain by electroporation.
Transposon Mutagenesis
Rationale For Procedure
From plasmids tested in the relative growth experiments, we chose plasmid pSA2
for further study. Using restriction analysis, we determined the size of pSA2 to be 24.4
kb. We suspected that its large size would complicate the genetic manipulations we
intended to use in the study of the effect of plasmid carriage on bacterial growth. S.
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aureus has an intrinsically low transformation efficiency compared to many well-studied
genera; the efficiency of transformation is approximately 10'4 of the frequency observed
in E. coli for DNA of the same size. Furthermore, the efficiency of transformation
decreases dramatically with DNA size (64). Faced with these transformation limits, we
decided to reduce the size of the DNA by dividing pSA2 into two fragments and cloning
these fragments individually into an E. coli vector. This afforded us two advantages: (i)
we were now working with E. coli, which has a higher transformation efficiency, and (ii)
the plasmid size had been reduced as the subclones were roughly half the size of intact
pSA2. Improving transformation efficiency was critical because we intended to generate
a large number of point mutations in the pS A2 segments and recover them as independent
clones. Using E. coli would improve our ability to screen many transformants and isolate
mutants from all regions of pSA2.
Another important consideration in our design was to generate random mutations
throughout the DNA. Random mutagenesis works on the premise that each gene has a
significant probability of affecting growth and, therefore, should be subject to analysis.
This approach would also allow us to locate genes with different levels of growth
reducing activity. We chose a transposon based system because the antibiotic cassette
associated with the transposon would serve as a convenient marker for selecting mutants.
Additionally, we chose a system that left a frameshift mutation at this site after the
transposon was enzymatically removed. Removal of the transposon was essential
because its internal antibiotic resistance genes would confound the process we wanted to
measure. In addition to frameshift mutations, the transposon based system introduced
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stop mutations in two of six reading frames, which increased the probability of
inactivating genes whose protein negatively affected the growth of the cell.
Procedure
Phase I: Cloning pSA2 Fragments
We divided pSA2 into 11.5 kb and 12.9 kb fragments using the enzymes Bel I and
Sal I, two restriction enzymes that each cut the plasmid once. Indeed, this was the only
pair of commercially available enzymes that cut uniquely and produced a pair of
fragments that were similar in size but sufficiently different to be easily discriminated by
gel electrophoresis. The two fragments were individually cloned into the multicloning
site (MCS) of pBluescript® II SK + phagemid (Stratagene, #212205), a 2.96 kb E. coli
vector with an ampicillin resistance marker. pBluescript contains Sal I in the MCS but
does not have a Bel I site. We engineered pBluescript to accept the pSA2 fragments by
introducing a Bel I site. To do this, we cut pBluescript with Sma I and Sal I, removed the
excised fragment and ligated Bel I linkers [New Englab Biolabs: NEB #S1035S)
d(pCTGATCAG)] to the Sma I end of pBluescript. The 11.5 and 12.9 kb fragments of
pSA2 were separately ligated to this linearized vector with Sal I and engineered Bel I
ends. Separate ligation pools with the 11.5 kb or the 15 kb pSA2 fragment were used to
transform E. coli SURE2 cells (Stratagene) by electroporation (9). Transformants were
selected by plating the cells on TSA with ampicillin (50 g/ml). Figure 2 illustrates these
steps. Plasmid minipreps were prepared from colonies appearing on these plates using
Qiagen Spin Kit (Valencia, California) with vacuum manifold. Plasmid DNA was
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Figure 2. Method used to clone pSA2. Two fragments of plasmid pSA2 were cloned
individually in the E.coli vector, pBluescript, using two unique restriction sites, Bel I and
Sal I. pBluescript does not have a Bel I, so this site was added. Ampicillin was used as
the selective marker for identifying clones. A clone containing the smaller fragment was
named p62 (11.5 kb); a clone containing the larger fragment was named p54 (12.9 kb).
These clones were used in random mutagenesis experiments.
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analyzed by gel electrophoresis to identify clones with the predicted banding patterns. To
confirm the identity of the cloned fragments, we performed double digests using Spe I
and Xho I, restriction sites located in the MCS of the vector on either side of the cloned
fragment. If the smaller pSA2 fragment was successfully cloned, it should produce three
bands when digested with these enzymes because it contained an Xho I site, whereas if
the larger pSA2 fragment had been successfully cloned it would produce only two bands.
A successful clone containing the 11.5 kb pSA2 fragment was named p62 (14.46 kb) and
the clone containing the 12.9 kb fragment was called p54 (15.86 kb). The two clones
were used separately in the transposon mutagenesis protocol described below.
Phase II: Random Transposon Mutagenesis
Figure 3 outlines the major steps in the procedure for transposon mutagenesis of
the 11.5 kb pSA2 fragment in p62. Random mutations were generated in p62 and p54
clones using the GPS-Linker scanning system from New England Biolabs (Beverly,
MA). The system uses a Tn7-based transposon-transposase combination that will
ultimately lead to the insertion of 15 base pairs at random positions in the target DNA.
We chose pGPS4, a 3.9 kb E.coli plasmid, for the transposon donor. The plasmid
contains a 1.38 kb transposon with an internal chloramphenicol resistance marker. The
ends of the transposon are bounded by Pme\ restriction sites.
Mutagenesis was performed according to the NEB kit instructions. The procedure
was the same for p62 and p54. Simply, 0.02 pg of pGPS4 transposon donor DNA was
added to 0.08 pg of p62 or p54 target DNA. Next, 1 pi of TnsABS transposase was
added. The mixture was incubated for 10 minutes at 37°C to allow the DNA to assemble
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Figure 3. Procedure for random transposon mutagenesis. Random transposon
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only once, in varied positions of the pS A2 DNA, interrupting every gene of the plasmid.
Mutated clones were identified by screening for chloramphenicol resistance. DNA
analysis confirmed that clones had mutations in the plasmid DNA and not the vector.
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for the transposition reaction. At this point, we added 1 pi of Start solution and extended
the incubation for another hour at 37°C. This incubation allowed the strand transfer
segment of the transposition reaction to take place. At the end of that time, the reaction
tube was transferred to a 75°C waterbath and incubated for an additional 10 minutes to
inactivate the transposase.
Electroporation was used to transform E. coli XL-1 Blue MRF' with volumes of
the undiluted transposon reaction mixture. Briefly, we added 40 pi of the electroporationready cells to a cold 1.5 ml microcentrifuge tube and added 1 or 10 pi of the reaction
mixture. The cells remained on ice for 1 minute. Next, we transferred the mixture of
cells and DNA to a cold, 0.2 cm electroporation cuvette. The cells were electroporated
using the Bio Rad Gene Pulser with control settings at 200 Q, 25 pF capacitance and 2.5
kV. Immediately after electroporation, the cells were covered with SOC medium (20
mM glucose, 20 g tryptone [Difco], 5 g yeast extract [Difco], 0.5 g NaCl, 10 ml 250 mM
KC1, 5 ml 2M MgCl) and incubated for 1 hour at 37°C with shaking to allow recovery
from the electric shock.
After transformation, the mixture of cells and DNA was diluted with 1 ml LuriaBertani (LB) broth (10 g tryptone [Difco], 5 g yeast extract [Difco], 10 g NaCl, per liter
pH 7.0) and incubated for 1 hour at 37°C with aeration. This was to allow expression of
the chloramphenicol drug resistance before plating on selective medium. The
transformation mixture was then spread on TSA plates containing 15 pg/ml
chloramphenicol and 50 pg/ml carbenicillin. Colonies that grew on this double selection
medium after overnight incubation at 37°C were randomly picked. Plasmid DNA was
isolated from each clone and screened by DNA restriction analysis. Each mutant of p62
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and p54 was given a unique designation. As a group they were collective referred to as
p62LS and p54LS. For clarity, the procedures for p62LS and p54LS will be described
separately.
p62LS: Briefly, 318 colonies of putative p62 mutants were individually selected and
inoculated separately into 5 ml Terrific broth (124) (12 g tryptone [Difco], 24 g yeast
extract [Difco], 4 ml glycerol, 0.17 M KH2PO4 and 0.72 M K2HPO4) supplemented with
2.2 pi chloramphenicol (15 pg/ml) and 5 pi carbenicillin (50 pg/ml). The cultures were
grown overnight at 37°C with aeration. Plasmid DNA was extracted using Qiagen Spin
kits using a vacuum manifold. The DNA was stored at 4°C in 50 pi Tris (pH 8.5) for
later use.
Individual isolates in the p62LS collection were tested to eliminate clones that
were not useful for further study due to any of the following reasons:
1.

The clone did not include the transposon sequence;

2.

The clone contained more than one copy of the transposon sequence;

3.

The transposon was located in the vector sequence rather than in the pSA2
segment;

4.

The pSA2 segment was rearranged or otherwise disturbed by the manipulations.
We examined each of the p62LS clones by digesting 1.5 pi of DNA with three

restriction enzymes: Sac I (or Sac II), Kpn I and Bsp El. Sac \!Sac II and Kpn I cut at the
two ends of the vector DNA, while BspE I cuts close to the middle of the transposon
sequence. The digested DNA was separated by gel electrophoresis on 1% agarose gels.
Individual mutant clones were discarded if they failed to meet any one of three criteria:
(i) digestion with Sac I (or Sac II), Kpn I and BspE I, produced 3 and only 3 bands (ii)
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one band, representing the vector segment, must be exactly 2.9 kb in size and (iii) the two
non-vector bands must add up to the size of the pSA2 fragment plus the size of the
transposon (12.9 kb). We pooled 1 pg of DNA from all clones that met these criteria
(198 clones). This mixture of mutated DNA clones was designated the p62LS transposon
pool. We determined the concentration of the pooled DNA using a TKO 100
Fluorometer (Hoefer Scientific Instruments, San Francisco).
p54LS: Briefly, 336 colonies of putative p54 mutants were individually selected and
inoculated separately into 5 ml Terrific broth (124) (12 g tryptone [Difco], 24 g yeast
extract [Difco], 4 ml glycerol, 0.17 M KH2PO4 and 0.72 M K2HPO4) supplemented with
2.2 pi chloramphenicol (15 pg/ml) and 1 pi cadmium (20 pg/ml). The cultures were
grown overnight at 37°C with aeration. Plasmid DNA was extracted using Qiagen Spin
kits with vacuum manifold. The DNA stored at 4°C in 50 pi Tris pH 8.5 for future use.
The individual isolates in the p54LS collection were tested using the criteria described for
p62LS to eliminate clones that were not useful for further study.
We examined each of the p54LS clones by digesting 1.5 pi of DNA with three
restriction enzymes: Sac I (or Sac II), Xho I and Bsp EL Sac MSac II and Xho I cut at the
two ends of the vector DNA, while BspE I cuts close to the middle of the transposon
sequence. The digested DNA was separated by gel electrophoresis on 1% agarose gels.
Individual mutant clones were discarded if they failed to meet any one of three criteria, as
established in the methods for p62LS: (i) digestion with Sac I (or Sac II), Xho I and BspE
I, produced 3 and only 3 bands (ii) one band, representing the vector segment, must be
exactly 2.9 kb in size and (iii) the two non-vector bands must add up to the size of the
pSA2 fragment plus the size of the transposon (14.3 kb).
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Phase III: DNA Sequencing
The restriction map of the plasmid was made using pDRAW32 from data
obtained from multiple restriction endonuclease reactions, either singly or in combination
with another enzyme (double digests). We analyzed the DNA agarose gels using the
Bioimage software from Genomic Solutions (Ann Arbor, MI), which provided us with
the fragment sizes. Next, we compared the sizes of the DNA bands generated by the
Bioimage software for each single restriction enzyme digest with the bands generated
from double restriction enzyme digests to obtain the most accurate size of pSA2.
For the purpose of DNA sequencing, we selected clones from the collection of
198 isolates of p62LS and 176 isolates of p54LS that had the transposon located at
approximately 0.5 kb intervals throughout the pSA2 segment. The transposon includes
unique terminal sequences that can be used as primer sites for upstream and downstream
sequencing. Sequencing primers (Primer N and Primer S) were supplied in the NEB
linker scanning kit. These primers were used to sequence in both directions from the site
of the transposon in the selected clones. Sequencing was performed by the Loma Linda
University CORE Sequencing Facility (Loma Linda, CA) and by Davis Sequencing, LLC
(Davis, CA). We used the computer programs, Sequencer version 3.0 and BLAST (Basic
Local Alignment Search Tool) to analyze the data and to assemble the fragmented
sequences into one continuous sequence. The data allowed us to precisely identify the
locations of the transposon in the selected clones and it provided us with sufficient
information to assemble the complete sequence of pSA2. The plasmid drawing program
Redasoft Visual Cloning 3.0 was used to generate a plasmid map of pSA2, showing the
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locations and transcriptional orientation of genes on the plasmid., Phase IV: Transposon
Removal
p62LS: The p62LS transposon pool DNA was enzymatically processed to remove the
transposon and its chloramphenicol resistance cassette (Figure 4). As described earlier
the transposon was designed with Pme I recognition sequences at its ends so that the
transposon is almost completely excised by Pme I digestion. After enzymatic cleavage
and religation of the Pme I cohesive ends, only 15 bp of DNA remain at the former site of
the transposon: 10 bp from the transposon (which includes a reconstituted Pme I site) and
5 bp from the pSA2 sequence which was duplicated as a consequence of the original
transposition event. The extra 15 bp also include termination codons in 2 of the 6
possible reading frames. This pool of DNA was designated the p62LS insertion pool. It
was electroporated into E. coli SURE cells and transformants were isolated by growth on
BHI agar with ampicillin (60 pg/ml). We obtained approximately 500
transformants. These were individually picked as before and processed to obtain plasmid
DNA. We used restriction analysis to determine that the transposon had been
successfully removed from the clones. Screening was performed using Pme I (cutting at
the former site of the transposon) combined with Sac I and Kpn I (cutting at the margins
of the vector). We pooled equal amounts of DNA from all clones that met criteria similar
to those described in the previous step.
p54LS: We were able unable to use p54LS in experiments to reconstitute pSA2 and test
the effects of various insertion mutations in this portion of the plasmid. The p54 clone
was very unstable. Attempts to enzymatically remove the transposon and introduce the
product into S. aureus resulted in loss of large segments of the p54 sequence or
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rearrangement of that sequence into new arrangements. We continued our experiments
by exploring the effects of random mutations in the p62 portion of pSA2.
Phase V: Reconstituting Complete pSA2 Plasmid
To regenerate a population of complete pSA2 plasmid molecules that have
various 15 bp transposon-generated insertions, it was necessary to extract the 11.5 kb
pSA2 fragment from the p62LS pool and ligate it to the remaining 12.9 kb of pSA2 (also
represented in the p54 clone), in the proper orientation. Figures 4 and 5 diagram this
process. The first step, performed in vitro, was to cleave the 11.5 kb pSA2 fragment in
p62LS from the pBluescript vector and, simultaneously, reduce the possibility that the
vector fragment would religate in a subsequent step. We did this by cutting the p62LS
DNA pool with four enzymes: Bel and Sal I to release the 11.5 kb pSA2 fragment from
the vector; and Sac I and Apa I to generate vector ends that are incompatible with the
wild type 12.9 kb pSA2 fragment.
In a separate reaction tube, we prepared the two fragments of wild type pSA2 by
cutting intact pSA2 DNA with three restriction enzymes: Bel I and Sal I to generate
fragments with ends compatible with the 11.5 kb portion of the p62LS pool; and Xho I
which cleaves the unmutated 11.5 kb fragment of pSA2. Cleavage of the unmutated 11.5
kb fragment prevented it from interfering with the subsequent ligation of the 12.9 kb
fragment from wild type pSA2 and the 11.5 kb fragment from the p62LS pool. The
reaction tubes were heated to 65°C for 20 minutes to inactivate Sal I and Xho I. Having
prepared the 11.5 kb mutated fragment from the p62LS pool in the first tube and the 12.9
kb fragment from pSA2 in the second tube, we then combined the two reaction tubes into
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one and used the Wizard™ Plus Miniprep DNA Purification System (Promega,
Madison, WI) to remove small DNA fragments. Next, we performed a phenol extraction
to remove the heat stable enzyme Bel I. The preparation was precipitated with 3 volumes
of ethanol and 1/10 volume of 3 M sodium acetate. The fragments were ligated by
adding concentrated T4 DNA ligase (1 million cohesive end ligation units) and 1/10
volume ligation buffer.
The goal was to examine these reconstituted mutant plasmids in S. aureus 8325-4;
however, we were forced to transform the ligated products into S. aureus AZ450 as an
intermediate step. Transformation into AZ450 was performed because the attempts to
introduce the reconstituted plasmid into 8325-4 yielded very few transformants. AZ450
may be more receptive because it lacks a restriction endonuclease that may target plasmid
sequences that had been propagated in E. coli. After electroporation into AZ450, the
cells were spread on BHI agar supplemented with 20 pg/ml cadmium to select
transformants. We randomly chose 480 colonies, grew individual cultures of these
clones, made plasmid mini-preps from each of them and screened them as before using
restriction analysis. From this number we identified 128 mutants that were free of vector
sequences, had a Pme I site and appeared to contain all pSA2 sequences in the proper
orientation. We electroporated DNA from each of these 128 mutants individually into S.
aureus 8325-4.
Even after cycling the plasmids through AZ450, transformation into 8325-4 was
very inefficient. For about 70% of the clones, Qiagen purified plasmid DNA did not
produce transformants in 8325-4. New plasmid DNA was prepared using Nucleobond

R

DNA Purification columns (BD Biosciences Clontech; Palo Alto, CA) that proved to be
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modestly more efficient. In every case, each of the mutant plasmids from AZ450 were
individually transformed into S. aureus 8325-4. After the mutated plasmids were
successfully introduced into 8325-4, we again made individual plasmid DNA preps and
confirmed that the plasmids contained one Pme I site and were not rearranged. We also
eliminated obvious duplicate restriction patterns. The total number of mutant clones
remaining after this final screening was 113.
Phase VI: Enrichment Experiments with pSA2 Mutants
The collection of 8325-4 clones carrying mutant pSA2 plasmids was used to
perform an enrichment experiment in which all 113 strains were co-cultivated (Figure 6).
The goal was to identify the mutations that were over represented in the population at the
end of the enrichment experiment compared to their initial numbers. The rationale for
this was that frameshift or nonsense mutations in genes on pSA2 would result in the
production of truncated or otherwise inactive proteins. If a plasmid gene negatively
affected the growth of its host cell, its inactivation would, presumably, relieve the effect;
cells with that plasmid mutation would grow more rapidly. Propagating a mixture of
cells carrying a variety of individually mutated plasmids would allow cells to overgrow
the others if their plasmids no longer retarded growth.
Enrichment experiments were performed simultaneously in triplicate to provide
replicate results. We grew individual cultures of the 113 clones overnight at 37°C with
shaking in 5 ml TSB supplemented with 20 mM cadmium to OD600 0.6. Two hundred
microliters from each of the 113 cultures were mixed in a 50 ml flask (total volume of
22.6 ml) and vortexed for 30 seconds. We inoculated 100 pi of this mixture into each of
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Insertion

Insertion

Insertion

Insertion

•Insertion

Pool of reconstituted pSA2 with random frameshifts in 11 kb region
Electroporate into
exo* S. aureus RN4220
Select for pSA2 markers

Prepare plasmid DNA from each clone
Test plasmid DNA by resitriction analysis
Transform qualified clones individually into S. aureus 8325-4
Pool equal samples of transformed cells

Propagate serially for 28 days
to enrich fastest-growing mutants
Transfers repeated 56 times

Figure 6. Enrichment experiment of pSA2 mutants. The collection of pSA2 molecules with mutations in random positions,
indicated by the location of the Pme I restriction site, were pooled together in equal amounts and serially propagated every 12
hours for 28 days. It was expected that cells possessing a plasmid with a mutation in a gene that caused diminished growth
would grow faster than other plasmid containing cells in the mixed population. At the end of the month-long enrichment, these
cells should represent a larger percentage of the population. Samples of the final culture were plated onto TSA plates.
Plasmids extracted from individual isolates were examined by restriction analysis.

three 2-liter flasks containing 500 ml of Nutrient broth and 1 |j.M cadmium. We saved the
unused portion of this inoculation mixture. It was centrifuged to pellet the cells,
resuspended in the original volume of 10% glycerol and stored at -80°C.
The flasks were incubated at 37°C with continuous shaking (200 rpm) in a Queue
Orbital Shaker, with serial subcultures inoculated every 12 hours for 28 days. For each
transfer, 100 pi was removed from the established culture and inoculated into a new flask
of 500 ml Nutrient broth supplemented with 1 pM cadmium. At the end of the 28-day
enrichment series, a final sample from each of the three replicates was diluted 10' in
Nutrient broth and 100 pi was spread on 10 plates of BHI agar supplemented with 75
pg/ml cadmium, 30 plates in all. The plates were incubated overnight at 37°C. Fortyeight isolated colonies were picked at random from the 10 plates made from each flask.
The plasmids carried by these 144 colonies were screened by restriction analysis.
For each of the three enrichment series, labeled Rl, R2, R3, we saved a 25 ml
sample at the end of each 24 hours of growth. Therefore, at the end of the month long
incubation period, we had 28 samples from each series. The samples were centrifuged
for 15 minutes at 7000 rpm at 4°C, resuspended in 25 ml of 10% glycerol and stored at 80°C.
Phase VII: Gene Confirmation
Using the unique Pme I site in the reconstituted pSA2 plasmids as our point of
reference, we designed pairs of oligonucleotide sequencing primers to precisely define
the sites affected by the 15 bp insertion mutations. We examined the physical
characteristics of proposed primers using Net Primer (Premier Biosoft International, Palo
Alto, CA) that provided us with information on the melting temperature, possible
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hairpins, tandem repeats, etc. The primer binding sites were 100-200 bases upstream or
downstream of the suspected mutation sites. Sequences with desirable characteristics
were ordered from Sigma Genosys (The Woodlands, TX). Plasmid DNA and the
corresponding primers were sent to the Davis Sequencing Center for sequencing. We
analyzed each sequence manually and with the aid of bioinformatic software, including
BLAST and ps/BLAST.
Analyzing pSA2 Mutants
Relative Growth Experiments of Mutated and Wild Type pSA2
Using the same method described previously (Figure 1), we performed relative
growth experiments, pairing cells carrying a mutated pSA2 with cells carrying wild type
pSA2. The mutated plasmids tested in these experiments were the three that appeared
most commonly in the enrichment experiment described above. The mutations were
located 3, 4 and 5 kb from the unique Bell site in pSA2. Relative growth experiments
were performed in 8325-4 as well as in the native host strain AZ28 from which plasmid
pSA2 was originally isolated. The experiments were run concurrently with a
representative of each mutant type to ensure that growth conditions were equivalent. The
purpose of these relative growth experiments was to verify that specific plasmid mutants
had significant effects on the growth rates of otherwise isogenic strains.
Phase II: Analysis of blaz
In order to understand the effects of transposon induced mutations in the (3lactamase genes of pSA2, it was necessary to determine if the gene is expressed
constitutively or only after induction. It was also necessary to determine how the enzyme
was affected by particular transposon-induced mutations, p-lactamase production was
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measured in three strains: S. aureus 8325-4 without any plasmids, 8325-4 with wild type
pSA2, and 8325-4 with pSA2 having a transposon generated mutation 5 kb from the Bel I
restriction site (a location within the structural gene for P-lactamase). Each of these three
strains was grown separately in TSB broth with and without 0.0625 pg/ml ampicillin
overnight at 37°C. This low concentration of ampicillin has no appreciable effect on the
growth or survival of penicllin-sensitive S. aureus 8325-4. One milliliter of each
overnight culture was centrifuged at 20, 000 x g for 5 minutes in 1.5 ml microfiige tubes.
The supernatants from the six cultures were transferred to 6 clean microcentrifuge tubes.
Volumes of 10, 25, 50 and 100 pi of the supernatants were individually applied to sterile
!4 inch paper disks (Difco 1599-33). Petri plates (150 mm diameter) with 50 ml of
Mueller-Hinton agar (Difco) supplemented with 0.125 and 0.25 pg/ml ampicillin were
uniformly inoculated with an overnight culture of S. aureus 8325-4 using sterile cotton
swabs. (These concentrations of ampicillin ordinarily prevent the growth of this strain.)
The undersides of the plates were marked off into sections. A single paper disk soaked
with a specified volume of supernatant from one of the six cultures was applied to each
section. The plates were incubated at 37°C overnight. Bacterial growth was expected in
a zone around a disk only if the disk contained sufficient p-lactamase to inactivate the
ampicillin. The absence of obvious bacterial growth was scored as “no growth”. If
growth was evident, the size of the growth ring was recorded.
Determining Plasmid Copy Number
To make conclusions about the effects of pSA2 plasmid on host cell growth it was
necessary to determine the average number of pS A2 molecules per cell (the “plasmid
copy number”) at different stages of culture growth.
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A culture of S. aureus AZ450 carrying wild type plasmid pSA2 was grown
overnight in Nutrient broth. A subculture in fresh Nutrient broth was incubated to
establish a log culture with an OD550 of 0.5. Using Qiagen mini-prep kits, we isolated
plasmid DNA from 3 different quantities of the overnight stationary phase cells and log
phase cells. The concentration of cells in the samples was determined by counting in a
Petroff-Hauser chamber under a phase contrast microscope. Plasmid DNA was extracted
from each cell sample size in 5 replicates to monitor variation. We digested 20 pi from
each of 30 pSA2 DNA preparations with Eco RI and applied the digests to 1% agarose
gels. Additional wells were filled with carefully measured amounts of highly purified
pSA2 DNA also digested with Eco RI. These amounts were 20, 40, 60, 80, 100, 120,
140, 160, and 180 ng. After electrophoresis at constant low voltage, the fluorescence in
the wells was compared visually and using optical scanning. Plasmid copy number was
determined by equating the fluorescence in the cell derived samples with the standards.
(Based upon the size of pSA2 [24.4 kb] we calculated that 1 pg of pSA2 DNA
corresponds to 3.69 x 1010 plasmid molecules.)
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RESULTS
Growth Rate Experiments
Using six measurements of AZ450, the doubling time for this strain without a
plasmid was determined to be 30.5 min ± 2.3 min (Table 4). The doubling times for
seven plasmid-containing derivatives of AZ450 were between 28.1 minutes and 33.8
minutes. These values are not significantly different from that of the parent strain. We
used information about the host strain’s growth cycle, cell density and the resistance
profile of the plasmids they care to design many subsequent experiments.
Relative Growth Experiments
Examining individual growth curves of S. aureus AZ450 and its derivatives where
the bacteria grow in separate cultures is not sensitive enough to detect growth rate
differences that are less than 5% of the plasmid-free strain. Instead, we employed a
method that exploits and amplifies the small differences in the growth rates of bacteria
over time by placing equal numbers of two phenotypically different strains in the same
culture medium and allowing them to grow together for an extended period. Given
sufficient time, any arbitrarily small difference in growth rates will be detectible as a
change in the relative numbers of the two cell types.
We observed a general trend in the relative growth of sensitive and resistant
strains of S. aureus. Tables 5 and 6 and Figures 7-14 show that, in most cases, sensitive
cells grew faster than plasmid-carrying resistant cells in the same culture. Table 5 lists
the results of relative growth experiments performed in S. aureus AZ450. Contradicting
the general trend, two plasmids (pSAl and pSKolO, [Table 5]) appeared to enable cells to
grow more rapidly than cells without the plasmid. In both cases plasmid-containing cells
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Table 4. Doubling times for AZ450 and six transformed AZ450 derivatives.0

oo

Strain

Slope

d Calculated

AZ450

9.90 x 10 -3

30.4 minutes

8.96 x 10 -3

Strain

Slope

d Calculated

1. AZ450[pl8Ery]

9.83 x 10 -3

30.6 minutes

33.6 minutes

2. AZ450[pl8Cd]

8.91 x 10 -3

33.8 minutes

9.67 x 10 -3

31.1 minutes

3. AZ450[pl8Neo]

9.90 x 10'3

30.4 minutes

1.06x10‘2

28.5 minutes

4. AZ450[pl5Ery]

9.89 x 10 -3

30.4 minutes

1.10 x 10'2

27.3 minutes

5. AZ450[pl4Cd]

1.07 x 10‘2

28.1 minute

9.42 x 10 -3

32.0 minutes

6. AZ450[pT181]

8.96 x 10 -3

33.5 minutes

c The doubling times were calculated for each of the seven S. aureus strains using the slope of the line segment which represents the exponential phase of the bacterial growth
cycle.

Table 5. Summary of relative growth experiments. Experiments were performed in S.
aureus AZ450 and the plasmid-carrying derivatives of AZ450.
Carrier
Strain

Effect of Plasmid

Cd, Amp, Kan,
Tob, Ery

AZ450

Sensitive cells decreased 97% *

21.9

Amp, Cd

AZ450

Sensitive cells increased 280%

pI9789

19.7

Cd, Ars

AZ450

No significant change in ratios

pSko10

19.4

Cd, Ars

AZ450

Sensitive cells decreased 97%*

pl4Cd

30.3

Cd, Amp, Ars

AZ450

No significant change in ratios

p41Cd

27.7

Amp, Cd, Ars

AZ450

Sensitive cells increased 320%

pl4Kan

22.2

Kan, Gen, Tob

AZ450

Sensitive cells increased 460%

Plasmid

Size
(kb)

Resistance
Markers

pSAl

28.0

pSA3

* Increase in the number of resistant cells to sensitive cells was attributed to phage-mediated transfer of
plasmid DNA to sensitive cells.
Ars- arsenate
p-lac- P-lactamase production
Cd- cadmium
Ery- erythromycin
Gen- gentamicin
Hg- mercury
(pHg- phenylmercuric acetate

Kan- kanamycin
Neo- neomycin
Tet- tetracycline
Tob- tobramycin
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Table 6. Summary of relative growth experiments. Experiments were performed using S.
aureus 8325-4, derivatives of 8325-4 possessing a plasmid, and the native hosts strain for
the plasmids listed below.
Plasmid

Size
(kb)

Resistance
Markers

Carrier
Strain

Effect of Plasmid

pSAl

28.0

Cd, Amp, Kan, Tob

8325-4
AZ145cured

Sensitive cells increased 160%
Sensitive cells increased 105%

pSA2

25.9

Amp, Cd, Hg

8325-4
AZ28cured

Sensitive cells increased 439%
Sensitive cells increased
>1000%

pSA3

21.9

Amp, Cd

8325-4

Sensitive cells increased 70%

pI9789

19.7

Cd, Ars

8325-4

Sensitive cells increased 80%

pI9789::Tn552

26.4

Cd, Hg, cpHg, As, plac

8325-4

Sensitive cells increased >
100,000%
(No resistant cells detected)

pl4Cd

30.3

Cd, Amp, Ars

8325-4

Sensitive cells increased 280%

p39Cd

27.3

Kan, Gen, Tob

8325-4

Sensitive cells increased 70%

p39Kan

23.7

Kan, Gen, Tob

8325-4
AZ64cured t

Sensitive cells increased 970%
Sensitive cells decreased 75%

f The increase in the number of resistant cells compared to the sensitive cells was due to differences in the
growth rate of the two strains. Phage-mediated transfer of plasmid DNA was not a factor in this
experiment.
As- arsenate
P-lac- P-lactamase production
Cd- cadmium
Ery- erythromycin
Gen- gentamicin
Hg- mercury
(pHg- phenylmercuric acetate

Kan- kanamycin
Neo- neomycin
Tet- tetracycline
Tob- tobramycin
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Figure 7. The relative growth of S. aureus AZ450 and AZ450 containing the resistance
plasmid, pl4Kan. AZ450 without the resistance plasmid is sensitive to kanamycin,
gentamicin, and tobramycin. A mixed culture of the two strains was grown in Nutrient
broth without antibiotics. Error bars represent 95% confidence intervals.
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Figure 8. The relative growth of S. aureus AZ450 and AZ450 containing the resistance
plasmid, p!4Cd. AZ450 without the resistance plasmid is sensitive to cadmium,
ampicillin and arsenate. A mixed culture of the two strains was grown in Nutrient broth
without antibiotics. Error bars represent 95% confidence intervals.
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Figure 9. The relative growth of S. aureus AZ450 and AZ450 containing the resistance
plasmid, pSAl. AZ450 without the resistance plasmid is sensitive to cadmium,
ampicillin, kanamycin and trobramycin. A mixed culture of the two strains was grown in
Nutrient broth without antibiotics. Error bars represent 95% confidence intervals.
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Figure 10. The relative growth of aureus 8325-4 and 8325-4 containing the resistance
plasmid, pSAl. 8325-4 without the resistance plasmid is sensitive to cadmium,
ampicillin, kanamycin and tobramycin. A mixed culture of the two strains was grown in
Nutrient broth without antibiotics. Error bars represent 95% confidence intervals.
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Figure 11. The relative growth of S. aureus 8325-4 and 8325-4 containing the resistance
plasmid pI9789::Tn552. 8325-4 without the resistance plasmid is sensitive cadmium,
ampicillin and mercury. A mixed culture of the two strains was grown in Nutrient broth
without antibiotics. Error bars represent 95% confidence intervals. *Only 13 resistant
colonies were detected among 9971 colonies. Error bars are not meaningful for this data
point. The two remaining ratios are not represented because their values move towards
infinity.
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Figure 12. The relative growth of S. aureus 8325-4 and AZ28 with and without the
resistance plasmid, pSA2. 8325-4 and AZ28 without the resistance plasmid is sensitive
cadmium and ampicillin. Error bars represent 95% confidence intervals.
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Figure 13. The relative growth of S. aureus 8325-4 and AZ64 with and without the
resistance plasmid, p39Kan. 8325-4 and AZ64 without the resistance plasmid is sensitive
to kanamycin, gentamicin and tobramycin. A mixed culture of the two strains was grown
in Nutrient broth without antibiotics. Error bars represent 95% confidence intervals. For
AZ64, the error bars are smaller than the data point symbol.
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Figure 14. The relative growth of S. aureus 8325-4 and 8325-4 containing the resistance
plasmid, p39Cd. 8325-4 without the resistance plasmid is sensitive to cadmium, mercury
and ampicillin. A mixed culture of the two strains was grown in Nutrient broth without
antibiotics. Error bars represent 95% confidence intervals.
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became the majority during co-cultivation. The result with pSAl was especially
surprising because, in subsequent experiments, this plasmid retarded the growth of the
laboratory strain 8325-4 and the growth of its native host strain AZ145. This led us to
consider the possibility that something other than relative rates of growth was involved in
the AZ450[pSAl] result. We suspected, and later confirmed, that plasmid transfer had
occurred. Transfer systematically increased the number of plasmid containing cells.
To summarize the results of the relative growth experiments performed in S.
aureus AZ450: three plasmids (pSA3, p41Cd and pl4Kan) greatly reduced its growth
rate. The results with four other plasmids (pSAl, pI9789, pSKo10 and pl4Cd) were not
interpretable due to the confounding contribution of plasmid transfer.
Results for relative growth experiments using many of the same plasmids were
performed with 8325-4, which does not support plasmid transfer. In this host strain, the
results showed that plasmid carriage retarded cell growth. All eight plasmids tested in
8325-4 showed a significant increase in plasmid-free cells in the population during co
cultivation (Table 6).
In three cases the influence of plasmids on the growth rates of their native host
strains were also tested. Plasmids pSAl and pSA2 clearly retarded the growth of their
native host cells, as well as the laboratory strain 8325-4. Plasmid p39Kan, however,
allowed its native host AZ64 to outgrow the cured derivative of AZ64. The results were
accepted as presumptive evidence that AZ64 is genetically adapted to plasmid p39Kan.
However, we have not rigorously eliminated the possibility that AZ64 supports plasmid
transfer.
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Analysis of pSA2
Plasmid Mapping and DNA Sequencing
Before beginning work on pSA2, we conducted a thorough restriction analysis of
the plasmid using a large number of restriction enzymes that cut the plasmid from 1 to 10
times (Table 7). From these results we were able to deduce much about the organization
of pSA2 prior to obtaining DNA sequence information. Figures 15-17 represent examples
of DNA agarose gels showing restriction fragments of pSA2. Each of these gels was
analyzed digitally to determine the sizes of the DNA fragments by comparison to
reference lanes with fragments of known sizes. That analysis is summarized in Tables 810. The size of pSA2 was determined to be- 24.5 kb based on the restriction data. This
conforms well to the sequence data we generated which gives a size of 24.4 kb.
Knowing the size of pSA2 was crucial to the design of the mutagenesis
experiments that followed. We knew early in our investigation that we needed to
generate a large number of independent mutants in order to have some mutations in every
gene on the plasmid. The procedure would require a large number of transformation
events which are difficult to perform in S. aureus when the plasmid size is larger than 10
kb. We used the restriction information to dissect the plasmid into two fragments of
about the same size and clone them independently into vector plasmids. These smaller
molecules were somewhat easier to introduce into S. aureus by electroporation.
The restriction map that we generated from the fragment analyses were used in
the cloning and mutagenesis experiments. We have included the map for the segment of
DNA that we studied most intensively (Figure 18). We were able to locate many unique
restriction sites in pSA2, although most of these were of limited use because they were
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Table 7. List of restriction enzymes used to analyze Staphylococcus aureus plasmid
pSA2. All enzymes tested that did not have an enzyme recognition site are listed at the
end of the table.
Name of Enzyme

Number of Fragments

1

AatW

1

2

Acc\

5

3

Acii

5

4

4/71

1

5

Asel

9

6

Aval

1

7

Avrll

1

8

Bell

1

9

Bgll

5(6)

10

BgUl

5

11

BsaBl

5

12

BsrriRl

2

13

BsplAl

7

14

i&tBI

7(8)

15

BstHl

6

16

BstXl

frequent cutter

17

Clal

4

18

Dpnl

1

19

Dral

9

20

Drall

7

21

Eco9l

1

22

EcoRl

3

23

EcoRV

9(10)

24

Ehel

2

25

Fspl

1

26

Hhal

8

27

Hpal

4

94

28

HindVW

3

29

Kpnl

2

30

Msc\

3

31

MspAW

2
4

32
33

Ndel

7

34

Mel

2

35

M/I

6

36

Pad

6

37

M/I

3

38

Pvul

39

MhII

2

40

tad

1

41

tan

1

42

Sca\

8

43

tarFI

7

44

Sfd

7

45

Swa\

7

46

Mil

4 (three very close together)

47

Xbal

4

48

Mol

1

49

Mml

4

1(2)

Enzymes that did not cut pSA2 (23 total): Agel, Ahdl, d/tvNI, ApaLl, Bamdl, Bbsl,
Bspel, BsiWl, Cspl, Eagl, Mini, NgoMTV, Nrul, Pmel, Pvul, Sad, Sadi, Sfil, SgrAl,
Smal, Spel, Sphl, Stul
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Figure 15. DNA gel used to determine the size of pSA2. The size of the bands in the gel
was determined using the Bioimage software from Genomic Solutions. We used this
data to compile a restriction map of pSA2.
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Table 8. List of restriction enzymes and the banding sizes used to determine the size of
plasmid pSA2. This table corresponds to the gel in Figure 15.
Restriction Enzymes
Hind III

Xbal

Pac I

Ncol

Clal

12.12

12.38

6.92

11.39

8.49

6.63

4.90

4.61

8.10

6.92

4.90

4.17

3.43

3.00

5.57

1.27

2.84

2.4

1.10

3.05

1.63

0.83*

0.45*

24.42

24.48

1.10
Total size (kb)

24.92

24.29

24.40

X Band size obtained from DNA gel of pSA2 in Figure 16 for the same restriction enzyme (see Table 9).
* Band size obtained from DNA gel of pSA2 in Figure 17 for the same restriction enzyme (see Table 10).
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Figure 16. DNA gel used to determine the size of pSA2. The size of the bands in the gel
was determined using the Bioimage software from Genomic Solutions. We used this
data to compile a restriction map of pSA2.
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Table 9. Lists of restriction enzymes and the banding sizes used to determine the size of
plasmid pSA2. This table corresponds to the gel in Figure 16.
Restriction Enzymes

Total size (kb)

Nco\

Nco I- Nhe I

Nco I- Pvu II

Nco I- Sal I

11.25

8.24

8.24

12.10

8.12

8.12

6.62

8.61

3.15

3.18

5.06

3.26

1.08

2.65

3.26

1.09

0.83

1.08

1.09

0.83

0.83

0.71

24.10

24.98

24.43
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Figure 17. DNA gel used to determine the size of pSA2. The size of the bands in the gel
was determined using the Bioimage software from Genomic Solutions. We used this
data to compile a restriction map of pSA2.
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Table 10. List of restriction enzymes and the banding sizes used to determine the size of
plasmid pSA2. This table corresponds to the gel in Figure 17.
Restriction Enzymes

Total size (kb)

Nhe I- Aat II

Nhe I- Sal I

Nhe I- Xho I

Nhe I- Avr II

15.03

11.83

12.4

12.66

5.48

10.21

9.54

9.11

2.64

2.61

2.63

2.63

23.15

24.65

24.57

24.4
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clustered closely together. However, we used Xho I and Kpn I to clone pS A2 as two
fragments in pBluescript. Furthermore, the unique Xho I cleavage was regularly used to
check the integrity of the 11.5 kb portion (cloned in pBluescript and
designated p62). The two cleavages made by Kpn I were valuable in confirming the
structure of the 12.9 kb portion (cloned in pBluescript and designated p54). These
restriction sites were also indispensable for the random mutagenesis experiments
performed using the GPS-Linker Scanning Kit from New England Biolabs (NEB).
The GPS-LS Kit from NEB allowed us to generate a large number of random
mutations in pSA2 using a Tn7 based transposon. The insertion of the transposon also
allowed us to map and sequence the plasmid using the supplied N and S primers. Figure
19 show a map of pSA2 delineating the location of genes on this plasmid. It is interesting
to note that pSA2 possesses genes mainly involved in resistance to chemical agents. It
contains the (3-lactamase operon, an antibiotic resistance determinant that consists of the
genes blaZ, blaRl and

located in the transposon Tn552 and encodes resistance to p-

lactam drugs. It also encodes resistance to the heavy metal, cadmium, conferred by cadD
and cad X. The presence of these resistance genes were inferred by antibiotic
susceptibility tests performed on AZ450[pSA2] and 8325-4[pSA2],
Sequence analysis using BLASTn (nucleotide-nucleotide searches) showed that
pSA2 shares sequences with several other S. aureus plasmids, especially within the
region corresponding to the staphylococcal transposon Tn552. pSA2 shows the strongest
homology to 5 staphylococcal plasmids: pLW043 (57.9 kb, encoding vancomycin
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Figure 19. A plasmid map of pSA2 showing the location and direction of genes. pSA2 is a 24.4 kb plasmid obtained from a
methicillin resistant S. aureus clinical isolate. The plasmid has only one antibiotic resistance gene (ampicillin) and one heavy
metal resistance gene. Most of the genes on this plasmid are involved in plasmid retention and propagation.
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Figure 20. Clustal W alignment of the BlaZ protein sequence from pSA2, Tn552 and five other staphylococcal plasmids.
Key
Yellow
represents a change in the protein sequence for plasmids other than pSA2.
*
means that the amino acid residues in that column are identical in all sequences in the alignment
means that conserved substitutions have been observed for residues in this column
means that semi-conserved substitutions are observed for residues in this column
blank
means that this column contains dissimilar amino acid residues
represents the point at which a stop codon appears in mutated pSA2. The resulting peptide contains
only 88 amino acids instead of the 281 amino acids of the normal protein.

BlaZ Clustal W alignment
Tn552
pSA2

PLW043
pMW2
pN315

MKKLIFLIVIALVLSACNSNSSHAKELNDLEKKYNAHIGVYALDTKSGKEVKFNSDKRFA
MKKLIFLIVIALVLSACNSNSSHAKELNDLEKKYNAHIGVYALDTKSGKEVKFNSDKRFA
MKKLIFLIVIALVLSACNSNSSHAKELNDLEKKYNAHIGVYALDTKSGKEVKFNSDKRFA
MKKLIFLIVMALVLSACNSNSSHAKELNDLEKKYNAHIGVYALDTKSGKEVKFNSDKRFA
MKKLIFLIVIALVLSACNSNSSHAKELNDLEKKYNAHIGVYALDTKSGKEVKFNSDKRFA

★ ★★★★★★★★ •

Tn552
pSA2

60
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60

pMW2
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YASTSKAINSAILLEQVPYNKLNKKVHI jNKDDIVAYSPILEKYVGKDITLKELIEASMTY

PN315

YASTSKAINSAILLEQVPYNKLNKKVHI jNKDDIVAYSPILEKYVGKDITLKELIEASMTY 12 0

PLW043

12 0
12 0
120
120

★ ★★★★★★★
Tn552
pSA2
o
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PLW043
pMW2
pN315

SDNTANNKIIKEIGGIKKVKQRLKELGDKVTNPVRYEIELNYYS PKSKKDTSTPAAFGKT 180
SDNTANNK11KEIGGIKKVKQRLKELGDKVTNPVRYEIELNYYS PKSKKDTSTPAAFGKT 180
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SDNTANNKIIKEIGGIKKVKQRLKELGDKVTNPVRYEIELNYYSPKSKKDTSTPAAFGKT 180
SDNTANNKIIKEIGGIKKVKQRLKELGDKVTNPVRYEIELNYYSPKSKKDTSTPAAFGKT 180
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Figure 21. Clustal W alignment of the Blal protein sequence from pSA2, Tn552 and five other staphylococcal plasmids
Key
Yellow
represents a change in the protein sequence for plasmids other than pSA2.
*
means that the amino acid residues in that column are identical in all sequences in the alignment
means that conserved substitutions have been observed for residues in this column
means that semi-conserved substitutions are observed for residues in this column
blank
means that this column contains dissimilar amino acid residues

Blal Clustal W alignments
Tn552
pSA2
pLW043
pSE-12228-05
pMW2
pN315
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Figure 22. Clustal W alignment of the BlaRl protein sequence from pSA2, Tn552 and five other staphylococcal plasmids.
Key
Yellow
represents a change in the protein sequence for plasmids other than pSA2.
represents a change in the protein sequence for pSA2
Pink
represents an additional change in the DNA for a plasmid other than pSA2 which is not shared by another
plasmid.
represents an additional change in the DNA for a plasmid other than pSA2 which is not shared by another
plasmid.
means that the amino acid residues in that column are identical in all sequences in the alignment
means that conserved substitutions have been observed for residues in this column
means that semi-conserved substitutions are observed for residues in this column
blank
means that this column contains dissimilar amino acid residues
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resistance Genbank AE017171), pMW2 (20.7 kb (10), Genbank AP004832), pN315
(24.7 kb (63), Genbank AP003139), pSE-12228-05 (24.4 kb, from Staphylococcus
epidermidis Genbank AEO15934) and an unnamed and unannotated 21 kb S. aureus
plasmid (Genbank AF128883) (Figures 20, 21, 22). The genome of two of the host
strains for these plasmids, S. aureus MW2 and S. aureus N315, have been completely
sequenced. These strains have been associated with MRSA outbreaks in the hospital and
community (10, 62).
Random Transposon Mutagenesis
We used the unique restriction sites Bel I and Sal I, as markers. These two
restriction enzymes cleaved pSA2 into a 11.5 kb fragment and a 12.9 kb fragment. We
arbitrarily made the Bell site our point of reference on the plasmid map and measured the
distance of all genes from this starting position. We were able to generate a large number
of independent insertion mutants, each created by the random insertion of the transposon
into p62 (the 11.5 kb fragment of pSA2).
Analyzing the locations of the insertion mutations, we identified 480 that were
distributed throughout the 11.5 kb region. We joined the 11.5 kb segment of these clones
to the remaining 12.9 kb to recreate intact pSA2 molecules with insertion mutations
within the 11.5 kb segment. These were individually electroporated into S. aureus
AZ450, individually recovered as intact plasmids and then separately electorporated into
8325-4. The process yielded 113 distinctive pSA2 mutants in 8325-4. Equal numbers of
cells carrying each of these plasmids were mixed and grown together through 56 serial
cultures over 28 days (>1300 generations). The intent of this series was to enrich the
mixture for clones capable of more rapid growth. They should become the predominant
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members of the mixed population. Using this working premise, we were able to identify
a number of genes influencing growth. Figure 23 depicts the locations of 112 plasmid
mutations detected in randomly picked clones from the final flask of the enrichment
series. More than 80% of the cells had plasmids with mutations clustered within a 3 kb
region. We determined this by using the unique Pme\ site and mapping the distance of
this site from either Bell or Sail. We confirmed the position of the Pmel site by
sequencing. To reiterate, the mutated gene is marked by the presence of a Pmel site that
was introduced into pSA2 by transposonon mutagenesis. There are no Pmel sites in wild
type pSA2.
Most of the insertion mutations that resulted in a growth promoting effect reside
within a 3 kb region of pSA2. This interval includes three genes in the p-lactamase
operon, blaZ, blaRl and blal, and two open reading frames which are similar to the
abortive infection protein, abiK, from Lactococcus lactis. Approximately one-third of the
mutations are located in the P-lactamase operon in Tn552, while 60% of the mutations
are found in the two copies of the abortive infection protein and the remaining mutations
(< 5%) are scattered over the rest of the 11.5 kb portion of pSA2. The two open reading
frames were putative abortive infection proteins because they had > 80% homology to
AbiK from L. lactis. We have not determined if these genes are functional in pSA2.
However, the high frequency of mutations recovered within this gene suggests that they
code for proteins products that exert a negative effect on the growth of the host cells.
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Figure 23. A histogram of the genes on pSA2 that affect the growth of the host
bacterium. When mutated, these genes have a growth promoting effect on the host cell.
Accordingly, in wild type pSA2, these genes would have had a growth reducing effect on
the host cell.
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Figure 24. The relative growth rate of three strains of S. aureus. The blue line is a relative
growth experiment between 8325-4 and 8325-4[pSA2], where 8325-4 without the plasmid is
sensitive to ampicillin and cadmium. The pink line is a relative growth experiment between
8325-4 [pSA2B5] and 8325-4[pSA2]. 8325-4 with the mutant plasmid is sensitive to
ampicillin but resistant to cadmium. pSA2B5 is mutated pSA2 with a nonsense mutation in
blaZ. The yellow line is a relative growth experiment between the clinical isolate AZ28
without and without pSA2. For AZ28, the error bars are smaller than the symbols for the
data points and represent 95% confidence interval. For the other two experiments in 8325-4,
error bars cannot be represented because too few numbers of resistant cells were detected.
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Analysis of pSA2 Mutants
Relative growth experiments performed between 8325-4[pSA2] and 83254[pSA2B5] showed that the mutation in the p-lactamase gene, blaZ, accelerated the
growth of the host strain. S. aureus 8325-4 with pSA2B5 showed a growth pattern
similar to 8325-4 without a plasmid, in that the mutant plasmid caused the host bacteria
to grow faster than bacteria with wild type pSA2 (Figure 24). Wild type pSA2 expresses
resistance to ampicillin while pSA2B5 is sensitive to ampicillin.
In order to understand these results, additional information was necessary. We
needed to know if p-lactamase enzyme production in pSA2 was constitutive or inducible,
and whether or not the plasmid mutant pSA2B5 produced P-lactamase. Experiments to
examine the production level of this enzyme revealed that the p-lactamase gene is
constitutively expressed (Figure 25 a-d) since we detected large quantities of the enzymes
in pSA2-carrying cells, even in the absence of inducer (ampicillin). p-lactamase
production was indicated by the ability of 8325-4 to grow on lethal concentrations of
ampicillin when in proximity to concentration disks containing the supernatant of S.
aureus cultures carrying pSA2. The experiments also showed that pSA2B5 does not
produce P-lactamase; the supernatant from this strain was not able to protect 8325-4 from
the lethal effects of ampicillin in the agar plates.
These results prompted us to analyze the sequence of the p-lactamase gene in the
pSA2B5 mutant. Comparing the sequence of pSA2B5 with a prototype of the blaZ gene
from Tn552 showed that pSA2B5 is truncated. A stop codon (TAA) appears early in the
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Figure 25. Detection of p-lactamase production by pSA2. Low levels of ampicillin were
used to induce P-lactamase production in the overnight liquid culture. P-lactamase production is
detected by bacterial growth around the concentration disk. Two cultures of 8325-4[pSA2] were
grown overnight in TSB, one supplemented with 0.0625 pg/ml ampicillin. This concentration
does not prevent the growth of ampicillin sensitive 8325-4, but is sufficient to induce p-lactamase
production. A bacterial lawn of 8325-4, an antibiotic susceptible strain, was spread over TSA
plates supplemented with either 0.125 pg/ml (MIC) or 0.25 pg/ml ampicillin. These
concentrations prevent growth of ampicillin sensitive 8325-4. Sterile disks saturated with
different volumes of culture supernatants were placed on the bacterial lawn and these plates were
incubated overnight. The supernatant volumes (in pi) added to the filter disks are indicated in the
grids on the plate.
The plates pictured in a) and b) show the P-lactamase production by pSA2 when it is induced and
not induced, respectively. There is no difference in the size of the growth ring around the disks
for induced and non-induced pSA2. Notice that 8325-4 without pSA2 is sensitive to ampicillin.
Therefore no growth ring appears around disks inoculated with the supernatant from overnight
culture of the bacteria. The plates pictured in c) and d) show that pSA2B5 (labeled 5+6 on the
photographs) produces no P-lactamase. This result is the same as observed for 8325-4 without
pSA2.
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coding sequence (Figure 20). The BlaZ protein from Tn552 is 281 amino acids long,
whereas BlaZ from pSA2B5 is 88 amino acids long. This would explain the inability of
the mutated plasmid to produce p-lactamase. Sequence comparisons of other genes in the
p-lactamase cluster {blaZ, blaRl and blal) does not reveal why p-lactamase is
constitutively expressed in wild type pSA2, when it is inducible in Tn552 and other
plasmids that resemble pSA2.
Determining Plasmid Copy Number
We determined the number of copies of pSA2 in cells by comparing the
fluorescence released from pS A2 DNA obtained from a measured number of cells to the
fluorescence of highly purified pSA2 DNA. Relative fluorescence indicates that there are
four copies of the plasmid in exponentially growing cells and three copies in stationary
phase cells (Figure 26).

7.39 x 108

14.8 x108

7.39x 108
cells/ml

20

40

60

80

100

120

160

180 ng

Figure 26. Plasmid copy number determination. By comparing the relative intensity of
the DNA bands in the first three lanes (left to right) to the standards in the lanes
immediately following, we were able to determine the plasmid copy number of pSA2.
pSA2 exists in two copies in the cell.
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DISCUSSION
Antibiotic resistance is a biological phenomenon that cannot be eradicated. Long
before antibiotics were introduced into medical practice to reduce the number of deaths
caused by bacterial infections, nature had invented many of the resistance mechanisms
we are currently trying to circumvent. Many fungi and bacteria produce molecules with
antimicrobial properties to gain access to limited resources in competitive microbial
communities. Since many of these compounds interfere with fundamental molecular
processes, the species producing these antimicrobial substances, namely the
actinomycetes, needed also to protect themselves from the affects of these compounds.
As a consequence, antibiotic synthesis and antibiotic resistance have a common origin.
Additionally, molecular evolution occurred in species targeted by antibiotics selecting for
individuals that have acquired or developed resistance.
The appearance of resistant bacteria has been accelerated, in part, by non-medical
applications in agriculture where antibiotics are used as pesticides and in the cosmetic
industry where antibiotics are added to skin care products. Through commercialism and
our efforts to provide a better way of life for ourselves, we have flooded our environment
with antibiotics, the effects of which are far reaching. The impact of our indiscriminate
use of antibiotics will not be fully understood for some time. Therefore, to assume that
we will be able to completely reverse every antibiotic resistant pathogen into a sensitive
one is naive and unrealistic. However, careful management of antibiotics can lead to
significant reductions in the levels of resistance among bacterial species. Attempts to
tackle the problem of resistance should aim to improve the efficacy of antimicrobial
chemotherapy to levels similar to those observed when antibiotics were first introduced
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medically. At that time microbial populations, though heterogeneous, were much more
sensitive to antibiotics than the organisms we encounter today. This research should
provide insight on how to change the dynamics between sensitive and resistant bacteria
within a bacterial population.
Our results show that antibiotic resistant genes negatively affect the growth of
their host bacteria. This trend was consistently observed in S. aureus 8325-4 which is a
prophage-free strain. However, in S. aureus AZ450 which has one prophage, our data
showed that plasmid transfer obscured any effect that resistance may have had on growth
rate. We tried to determine the means of plasmid transfer by testing the two most
probable mechanisms, conjugation and transduction. By successive spontaneous
mutations, we constructed a derivative of 8325-4 that was resistant to rifampicin and
fusidic acid. The resulting strain, designated AZ1000, was thereby easily distinguishable
from AZ450. The doubly resistant strain AZ1000 was mixed in various ratios with
AZ450[pSAl] and incubated. The mixture was then screened for cells resistant to
rifampicin and fusidic acid (markers for AZ1000), and ampicillin (marker for pSAl).
The appearance of triply resistant colonies in fairly large numbers indicated that
AZ450[pSAl] could donate pSAl to AZ1000. These results suggested that pSAl might
be a conjugative plasmid with a relatively high frequency of transfer. However, when we
performed similar experiments using 8325-4[pSAl] and AZ1000, no plasmid transfer
was detected on triple selection plates. Because S. aureus 8325-4 is a strain devoid of
resident phages, this second result points away from conjugation and suggests that some
other process, probably transduction, was responsible for the transfer of pSAl from
AZ450 to AZ1000.
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Relative growth experiments performed in AZ450 were completed before we had
experimental verification of plasmid transfer. Plasmid transfer had the effect of
increasing the fraction of plasmid-containing cells in experiments using this strain. In
retrospect, we presume that experiments suggesting that AZ450[pSKol0] could outgrow
plasmid free AZ450 are similarly explained by the ability of AZ450 to donate its
plasmids to other cells. Consequently, most relative growth experiments using AZ450
cannot be accepted without further examination. Nonetheless, a few experiments using
AZ450 showed an increase in the relative number of plasmid-free cells. These can be
tentatively accepted as support for the hypothesis that resistance plasmids retard cell
growth. In fact, growth retardation by these plasmids may have been so great as to
overcome the opposing process of plasmid transfer.
In plasmid pSA2, resistant genes code for an enzyme that cleaves |3-lactam drugs
like penicillin and its derivatives. In the Introduction we described how P-lactam
antibiotics exert a bactericidal affect and how P-lactamase inactivates penicillin and other
p-lactams. In the model detailed by Archer and Bosilevac (8), p-lactamase production is
inducible. However, in the system we studied, enzyme production by pSA2 was
constitutive. We have not been able to determine the reason for this constitutive
expression because sequence analysis of the blaZ gene from wild type pSA2 does not
show any significant changes in amino acid sequence when compared with blaZ of
Tn552. Tn552 is a transposon commonly found on staphylococcal plasmids and encodes
resistance to p-lactam antibiotics. It is the prototype for genes in the p-lactamase operon.
Furthermore, we compared 6/0/and blaRl genes from pSA2 with those from Tn552.
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Again, we were not able to determine significant changes in the amino acid sequence of
these genes that would result in constitutive expression of P-lactamase.
We propose that the slow growth rate of strains carrying pSA2 is due to the
effects of the proteins encoded by the resistance genes and not due simply to energy costs
of protein synthesis. Before starting our relative growth experiments, we performed
theoretical calculations that determined that the replication and maintenance of DNA
from a 25 kb plasmid imposes a negligible energetic or metabolic burden to host cells.
By applying energy usage data obtained from Neijssel (87) to the genome of Escherichia
coli K-12 (4.6 Mb), genomic DNA synthesis uses approximately 3% of the cell’s energy
expenditure. The addition of a 25 kb plasmid would increase the energy expenditure of
the cell by only 0.016% E. coli K-12. This increase is due to the cellular machinery
replicating the plasmid DNA along with the bacterial chromosome. Protein synthesis
exacts a higher cost on the cell, but the addition of a 25 kb plasmid to E. coli K-12 only
raises the energy cost to the cell by approximately 0.3 %.
Working with the premise that protein function and not protein production was
energetically costly, we tried to understand the role that p-lactamase would play in the
energy usage of the cell in the absence of penicillin. First, let us review how
peptidoglycan synthesis occurs. Peptidoglycan (murein) comprises the bacterial cell wall
and consists of interlinked and repeating chains of N -acetylmuramic acid (NAM) and Nacetylglucosamine acid (NAG). Long chains of alternating NAG-NAM glycans are
joined by pentapeptide crossbridges. Penicillin is a molecular analogue of the D-alanylD-alanine (D-ala-D-ala) amino acids constituting the terminal portion of the pentapeptide
chain bound to NAM. The inhibitory effect that penicillin exerts on the cell is achieved
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when the (3-lactam binds to the active site of glycopeptide transpeptidase, the enzyme that
catalyzes the peptide linking between the pentapeptide side chains of NAM. Resistance
to penicillin is achieved by cleaving the p-lactam ring of penicillin such that it can no
longer bind to the active site of the transpeptidase. This allows murein synthesis to
continue uninhibited. Because penicillin resembles the D-ala-D-ala side chain enough to
effectively block cell wall synthesis, it is possible that the p-lactamase may attack the Dala-D-ala side chain, which is a structural analogue of its normal substrate. This would
slow murein synthesis and ultimately slow growth. Cells would have to generate more
murein subunits to repair and build the cell wall. However, this explanation is not
complete. P-lactamase is typically a secreted protein. It would seem that a secreted
enzyme should affect plasmid-containing and plasmid-free cells growing in the same
culture to approximately the same degree.
As presumed, this phenomenon should affect actively growing cells, in the
absence of antibiotics. Our relative growth experiments were designed to keep the cells
in log phase for the majority of the growth cycle. In a 12-hour cycle for the serial batch
cultures, the cells spent at least 8 hours in log phase and less than 2 hours in stationary
phase. This information is based on calculations we performed while designing our
relative growth experiments using data from the growth of cells in batch cultures. This
feature of the relative growth experiments was incorporated into the procedural details to
ensure that the cells were in the exponential growth phase for the majority of the growth
cycle. The aim was to prevent the cells from incubating in stationary phase for an
extended period of time as this phase of the bacterial growth cycle is when a significant
number of mutations occur in the DNA. We extended the log phase of these cultures by
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using a relatively small inoculum (100 jxl) in a large volume (500 ml). The cells would
not quickly exhaust the nutrients in the medium.
For our purposes, we performed the relative growth rate experiments using serial
broth cultures. Ideally, such experiments would be performed using a continuous growth
chamber (chemostat) but the ease with which S. aureus attaches to surfaces prevented the
use of a chemostat. Serial broth cultures inoculated every 12 hours and subjected to
constant shaking avoided the formation of biofilms on the surface of the culture vessel.
Cells growing in biofilms would have prevented uniform mixing and representative
sampling. This would have effectively prevented the determination of the ratios of
sensitive to resistant cells.
The use of culture flasks to conduct relative growth experiments is not novel to
our study. Schrag et al (105) and Ugolini et al (135) performed competition experiments
between bacterial strains under conditions similar to those described here. In both cases,
cells were allowed to reach stationary phase before being transferred to fresh medium to
encourage mutations. Both groups performed serial dilutions once daily, after overnight
growth, whereas we serially propagated our cultures on a consistent!2-hour cycle to
maintain actively growing cells.
It should be restated that the generation of mutations by Tn7 is random (12, 32,
120). Although most transposons have “hot spots” or preferential sites for inserting into
target DNA (33), this is not the case for Tn7. In fact, there are several transposons that
have an almost random insertion pattern (50, 56). Another important feature of the Tn7
transposon mutagenesis system is that there is a low frequency of multiple insertions in
the target DNA. Tn7 has target immunity (119) which allows it to scan the target DNA
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for existing copies of the transposon. Detection of Tn7 in the target DNA prevents the
insertion reaction.
Random insertion and gene inactivation allowed us to identify genes in the p62
fragment of pSA2 that have a negative effect on growth. A major discovery was the
presence of two copies of a gene similar to the abortive infection protein, abiK of
Lactococcus lactis, which exerted a strong negative effect on the growth of cells. L.
lactis is a gram positive, lactic-acid producing bacterium commonly used in the dairy
industry to make fermented milk products like cheeses and sour cream. Because of its
importance to the dairy industry, significant effort has been made to study L. lactis and
how it can be protected from infection by bacteriophages. Research on this subject has
generated a large body of information about anti-phage systems. Anti-phage systems
prevent the replication of viral nucleic acids and/or the dissemination of the
bacteriophage from cell to cell by producing proteins that interfere with viral processes.
To date, 20 abortive infection (Abi) proteins have been identified: A through L, N
through R, and T and U (17, 35). In spite of the large number of Abi systems identified,
they are poorly understood. What is known is that the genes for the abortive infection
proteins are usually plasmid encoded and protect the bacteria from phage infection after
the genetic material of the bacteriophage has entered the cell. Abi proteins prevent
proliferation and dissemination of the virus by irreversibly shutting down the phage lytic
cycle. It is believed that these systems use a variety of mechanisms that inhibit phage
DNA replication, transcription, translation, or processing of proteins. Abi proteins may
also produce their anti-phage effect by blocking assembly of the phage or by causing the
infected bacterial cell to lyse prior to the assembly of viable viral particles (134).
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Infected cells are killed either by the Abi protein itself or by phage damage to the cell
(44). There is some evidence that overproduction of Abi proteins in L. lactis may
negatively affect growth of the cell (3).
Although Abi proteins are being studied for their ability to protect bacterial cells
from bacteriophage infection and their genes have been introduced into other bacterial
strains important to the dairy industry (123), none of these proteins have previously been
discovered naturally in other bacterial species. Finding genes related to the Abi proteins
of L. lactis in S. aureus is a novel discovery. It probably represents an example of
horizontal gene transfer between Lactococcus and Staphylococcus, two gram positive
microorganisms. The means by which these genes entered S. aureus is not known since
they are not associated with a transposon.
We also found a gene in pSA2 that is similar to IclA which codes for another
protective protein from L. lactis, lactococcin 972. Lactococcin 972 is a bacteriocin that
kills other lactococci and gives L. lactis a competitive advantage in natural environments.
Like the Abi proteins, lactococcin is plasmid encoded (79). The Abi and lactococcin
genes in pSA2 indicate that horizontal gene transfer between S. aureus and other gram
positive bacteria can not be understated. For example, recent evidence confirms that the
vanA gene from Enterococcus has been transferred to S. aureus, ultimately resulting in
vancomycin resistant S. aureus (VRSA).
Indeed, it is likely that several genes present on pSA2 may affect the growth of
the bacterial cell carrying the plasmid. Most of our study and discussion has focused on
the effect of genes located on the p62 portion of the plasmid. Because of the difficulties
we experienced while working with the portion of pSA2 that corresponds to p54, we
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were unable to test the mutations we generated in this part of the plasmid. All attempts to
work with p54LS after the removal of the chloramphenicol resistant Tn7-based
transposon resulted in grossly rearranged DNA. From sequence data of p54 we suspect
that there may be an insertion sequence (IS element) contributing to the instability of this
portion of the plasmid DNA as it is known that these elements can cause DNA
rearrangements. We do not believe that the size of p54 has anything to do with its
instability. At 12.9 kb, p54 is smaller than pSA2 and might be expected to be at least as
stable as the intact plasmid. At each sampling event from the mixed cultures in the
relative growth experiments, a sample was also taken from a control flask containing only
plasmid-containing cells grown without antibiotic selection. Plating onto TSA without
antibiotics and subsequent replica plating onto media supplemented with antibiotics did
not show the presence of sensitive cells. These results indicate that pSA2 is stably
maintained in its host cells and that loss of the plasmid or its antibiotic resistance was
rare. Instead, we believe that the 3-4 kb fragment consistently lost from the p54 portion
of pSA2 is due to unusually high recombination activity around the Nhe I sites of the p54
fragment. Although we have had difficulty sequencing this area of the plasmid, the
presence of Bgl\\ sites suggests that IS elements may be present (19, 39, 127).
Therefore, to test the 54 side of the plasmid, it may be necessary to subclone this region
in smaller segments, mutate each fragment separately and study the effect of the
mutations on growth in S. aureus. This strategy assumes that the smaller fragments will
be more stable, although we have no direct evidence for this assumption.
Antibiotic resistance plasmids may not always exert a growth reducing effect on
their host cells. Figure 13 shows that p39Kan caused the native strain AZ64 to grow
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faster than the cured, plasmid-ffee version. This suggests that the plasmid and
chromosomal genome developed a synergy that allows the cells to grow rapidly when
both components are present. The work reported here, however, indicates that resistance
entails the expenditure of energy not required of sensitive cells. Consequently, the case
of p39Kan suggests that accommodations are possible. Plasmid p39Kan and the genome
of AZ64 may have experienced one or more genetic changes that compensate for the cost
of resistance by reducing the total cellular energy budget.
A case for compensatory mutations is not a difficult one to make. Indeed, there
are several published examples of compensatory mutations (14, 14, 70, 99, 105, 107).
Although experimental evidence for compensatory mutations has been discovered only in
Escherichia coli, Salmonella typhimurium and Mycobacterium tuberculosis, it is believed
that compensatory mutations occur in all bacterial species subjected to the selection
pressure of antibiotics. The prevailing view is that compensatory mutations occur at a
site(s) different from the resistance genes and that they alleviate the cost of resistance by
achieving cellular economies elsewhere. Compensatory mutations are believed to occur
sufficiently often to enable some resistance genes to persist within a population. For cells
carrying plasmid-encoded resistance genes, compensatory mutations usually occur in the
chromosome of a bacterial cell after the cell and the plasmid have co-evolved for an
extended period of time.
It should be noted that most of the work examining compensatory mutations
involve resistance genes located on the bacterial chromosome. This represents a more
permanent situation for the resistance gene than when it is located on a plasmid. If a
compensatory change occurred on the chromosome to accommodate a plasmid-borne
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resistance trait, one might suspect that loss of the plasmid would reduce the cell to a less
efficient state. The generation of compensatory mutations may also explain the
persistence of some plasmids within a cell, independent of plasmid addiction systems.
Additionally, many resistance traits that have compensatory mutations associated with
them involve changes in transcription or translation (e.g. tetracycline resistance and
aminoglycoside resistance). The effects of such resistance mechanisms are not limited to
the resistance proteins but extend to all cellular proteins such that the overall health of the
cell is affected. In our research, one plasmid out of the eleven tested likely showed
evidence of compensatory mutations. If this is so, then in our system, compensatory
mutations occurred 9% of the time. Possible reasons for the low frequency of
compensatory mutations in our system are: i) our cross section of plasmids studied may
not be representative of the larger bacterial population and ii) compensatory mutations
may have a lesser impact on fitness when plasmid genes are involved. Further research is
needed to provide evidence to support either hypothesis.
Whether or not we should expect compensatory mutations to occur in bacteria
may be correlated to and limited by the resistance mechanism and how costly it is to the
cell. Therefore, the degree to which each resistance mechanism affects growth and/or
metabolic processes should be tested and the information applied to novel strategies to
fight the problem of drug resistance. For example, compensatory mutations did not seem
to affect p-lactam resistance caused by the production of p-lactamase but they may play a
role in P-lactam resistance mediated by the chromosomally encoded, altered penicillin
binding protein, PBP2a.
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Our research provides support for a strategy to minimize the effects of antibiotic
resistance. We propose a strategy to combat the problem of antibiotic resistance that
exploits the small differences in growth between sensitive and resistant populations so
that over time there are more sensitive cells in both the clinical and community settings.
It requires that, after successful antimicrobial therapy in the hospital, the patient be
inoculated with sensitive bacterial strains to repopulate the normal microbiota.
Inoculation could take the form of a salve, soap or spray. Typically after sustained
antibiotic treatment, most of the resident bacteria, whether helpful or harmful, are
destroyed. It leaves the few remaining resistant cells to repopulate various niches in the
body. If sensitive cells are killed and only semi-resistant to severely resistant cells
remain, this means that the next acute infection is likely to be caused by a resistant strain,
making treatment more difficult, more costly and more life-threatening. By
reintroducing sensitive cells to the patient after treatment, you have increased the number
of sensitive to resistant cells. We have shown that when bacteria are grown together 1:1,
sensitive cells will outgrow the resistant cells given sufficient time. Accordingly, if
sensitive cells are introduced at a higher density than the remaining resistant cells, then
there will be a more rapid return to a predominately sensitive bacterial flora.
Our strategy has a basis in a current clinical approach, called bacterial
replacement therapy, which is used to treat or prevent disease. Treatment or prevention
of disease is attained when relatively innocuous strains of bacteria colonize the human
body and competitively exclude the growth of potentially pathogenic microorganisms.
One well documented example of bacterial replacement therapy is the area of probiotics.
Probiotics uses cultures of live microorganisms to improve the health and welfare of
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humans and animals by beneficially affecting the normal micro flora. The most
commonly used microorganisms are lactic-acid producing bacteria like Lactobacillus and
Bifidobacterium. These intestinal commensal bacteria are ingested to improve gastritis
and peptic ulcers caused by Helicobacter pylori. Another species, L. acidophilus.
reduces the viability of H. pylori by producing antimicrobial substances that inhibit its
growth (143). The principle of replacement therapy and probiotics is currently being
applied to the treatment of diseases like dental caries, otitis media and streptococcal
pneumonia. In fact, BLIS Technologies Ltd (http://www.blis.co.nz), a New Zealand
based company, commercially markets a product called BLIS K12 Throat Guard for the
treatment of streptococcal pharyngitis in young children (144). It contains Streptococcus
salivarius K12 which produces bacteriocin-like inhibitory substances (BLIS) that
discourage the growth of Streptococcus pyogenes, a known pathogen.
An important consideration for the strategy we propose is the realization that it
will only be successful if combined with other resistance control measures. This means
that the medical community will need to adhere to the prescriptions suggested by the
Centers for Disease Control (CDC) for reducing antibiotic resistance. Also, cutting edge
research should be conducted in the areas of medicine, pharmaceuticals and
biotechnology. Healthcare personnel, especially physicians and nurses must wash their
hands between patients. Doctors must avoid prescribing antibiotics for viral infections.
Usually doctors prescribe broad spectrum antibiotics initially to treat bacterial infections,
but often times the pathogen is not cultured or tested. This lapse should be corrected and
the microorganism should be cultured from an active infection, subjected to drug
susceptibility tests. Based on the drug susceptibility profile, the appropriate narrow
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spectrum drug should be prescribed as soon as possible to reduce the probability of
generating resistant strains in several microbiotic species. Patients should take their
antibiotics for the full course of treatment, as directed by a physician. Additionally,
consumers should not try to self-diagnose and take antibiotics prescribed to someone
else. We must find ways to curtail the indiscriminate commercialization of antibiotics
and their use in household cleaners and soaps, and as growth promoters or as pesticides in
agriculture. If control strategies are not used collectively then new drugs will quickly
become obsolete, antibiotic cycling will be a futile endeavor and we will have to rely
heavily on the slow and expensive process of developing new antibiotics to protect us
from a scourge that we have ourselves inflicted.
There are additional experiments that could be performed to extend this study.
Firstly, we could analyze other genes on pSA2 that have a growth reducing effect, such
as blal and blaRl from the (3-lactamase operon and the abi genes of the abortive infection
protein. Unfortunately, we would not use our previous method of plating onto selective
media because this would activate blaZ, a gene with a proven growth reducing effect.
Alternative methods of testing the effect of these genes on cell growth would include the
use of restriction analysis or colony lifts to observe the change in ratio of sensitive to
resistant cells over time. However, all these methods would still remain secondary to the
relative growth experiments which generate the samples to be tested.
Restriction analysis would be the most direct method of analyzing the data from
relative growth experiments. For each of the sampling points, the cells would be
harvested and their DNA enzymatically processed by restriction endonucleases. For
relative growth experiments where we compare the growth of the mutant to wild type
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pSA2, two sets of restriction enzymes should be used to produce distinctive banding
patterns that allow each of the DNA species to be accurately identified. We would then
look for an increase or decrease in the density of one of the banding patterns depending
on whether the mutant is no longer able to reduce growth. We postulate that there would
need to be a 50% difference in growth between the two strains in order for us to
maximize the results of a relative growth experiment, using this method. In instances
where it is difficult to determine a change in the density of the bands over time or if it is
difficult to observe the difference in the density of the bands for the sensitive and
resistant strains for any given sample, then it may be possible to perform colony lifts.
Cells would be plated onto medium without selection and transferred onto a membrane.
Next, the cells would be treated with chemicals to lyse them and release their DNA, and a
colormetric probe could be used to identify cells with a Pme I site. The Pme I site would
indicate that these DNA molecules contain a mutation. Comparison of the number of
colored dots on the membrane to the number of total colonies growing on the plates
should provide a ratio of the two DNA species.
Another aspect of this study that can support further research is the role of
compensatory mutations in gram-positive bacteria. As previously mentioned,
compensatory mutations usually occur on the chromosome of the bacterial cell and not
the resistance plasmid (80). One way to test for compensatory mutations in our system
would be to remove the plasmid from the native host strain or from a host strain that has
passed through many generations with an introduced resistance plasmid (>10,000
generations) and to compete the plasmid-free strain with the original plasmid containing
strain in mixed culture as have previously been described for the relative growth
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experiments. For successful comparison of the two strains, it would be important for the
plasmid and host genome to evolve together before the plasmid is removed. This would
increase the probability that a second site mutation occurred in the cell to compensate for
the deleterious effects of carrying a resistance plasmid. In our system, the native host cell
would be the best choice for identifying compensatory mutations because these cells were
once under constant selection pressure when these cells were part of an active infection.
The relative growth rates of the two strains could be compared by restriction
analysis and DNA gel electrophoresis. Briefly, plasmid DNA from the mixed culture
would be harvested at regular intervals and treated with restriction endonucleases that
provide an identifiable pattern for the resistance plasmid. The DNA from each sample
that has been collected over the course of the relative growth rate experiments, would be
loaded onto an agarose gel, electrophoresed and the density of the banding patterns would
be compared using a densitometer. If the density of the bands decreased from the initial
value determined for the mixed culture of sensitive and resistant cells, this would indicate
that the sensitive (plasmid-free) cells increased in number such that there were less
resistant cells in the mixed population than was represented at the start of the relative
growth experiments. This would suggest that a compensatory mutation in the
chromosome of the cell did not occur in the once co-evolved strain. If the density of the
bands increased from the initial value determined for the mixed culture of sensitive and
resistant cells, this would indicate that the resistant (plasmid-containing) cells increased
in number such that there were more resistant cells in the mixed population than was
represented at the start of the relative growth experiments. These are just some of the
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experiments that can be performed to expand our understanding of plasmid-host
interactions and the biological burden plasmid carriage places on the bacterial host.
Through this research, we have successfully shown that plasmid-encoded genes
can have a negative effect on the growth of the host bacteria. Based on our findings with
pSA2, we conclude that for bacteria, survival of harsh conditions comes at a price. All
the genes identified on pSA2 as causing slowed growth (genes of the p-lactamase operon
and the abi genes) serve to protect the cell, either from antibiotics or prophages, but are
also energetically costly to maintain. We have also provided some practical applications
for this research, especially ways to combat the rise in antibiotic resistant bacteria, and
we have added to the fundamental understanding of plasmid biology and bacterial
evolution.
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